Salt of tricyclic compound, crystal form and application thereof

Abstract

The invention discloses a salt of a tricyclic compound as well as a crystal form and application thereof, and particularly discloses a salt of a compound as shown in a formula (I) as well as a crystal form and application thereof. The salt of the compound as shown in the formula (I) and the crystal form of the salt have one or more advantages of good solubility, low hygroscopicity, good stability and the like, and have a better patent medicine prospect. # imgabs0 #

Description

[0001] This application claims the priority of Chinese Patent Application No. 2024101255891 with a filing date of January 29, 2024. This application incorporates the entire text of the above-mentioned Chinese patent application by reference. Technical Field

[0002] The present invention relates to the field of pharmaceutical technology, and particularly to a salt of a tricyclic compound, its crystal form and its applications. Background Art

[0003] The phosphatidylinositol 3-kinase (PI3K) protein family is divided into four major classes: I, II, III, and IV, and is involved in the regulation of various cellular functions such as cell growth, proliferation, differentiation, survival, and glucose metabolism. The four classes of PI3K proteins have different structures and functions, and among them, class I PI3K has been the most widely studied. Class I PI3K is further divided into four subtypes: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, and among them, PI3Kα is closely related to the occurrence and development of tumors. In recent years, inhibitors targeting PI3Kα have become a research hotspot for anti-tumor drugs at home and abroad.

[0004] WO2022161347A1 discloses a compound of formula (I) which has good inhibitory activity against PI3Kα.

[0005] Summary of the Invention

[0006] The present invention aims to provide a salt of a compound of formula (I), its crystal form and its applications.

[0007] In a first aspect of the present invention, there is provided a salt of a compound represented by formula (I), and the salt is maleate, hydrochloride, p-toluenesulfonate, hydrobromide, phosphate, oxalate, 2-naphthalenesulfonate or malonate of the compound represented by formula (I);

[0008]

[0009] In some embodiments, the salt is represented by any of the following structures:

[0010]

[0011]

[0012] In a second aspect of the present invention, there is provided a crystal form A of maleate of a compound represented by formula (I), and its X-ray powder diffraction pattern expressed in terms of 2θ angle has diffraction peaks at the following 2θ angles: 7.59° ± 0.20°, 15.17° ± 0.20°, 15.96° ± 0.20°, 16.92° ± 0.20° and 18.20° ± 0.20°.

[0013] In a preferred embodiment, the crystalline form A of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles and further has diffraction peaks at one or more of the following 2θ angles: 9.12° ± 0.20°, 10.09° ± 0.20°, 12.60° ± 0.20°, 17.30° ± 0.20°, 17.60° ± 0.20°, 19.79° ± 0.20°, and 20.90° ± 0.20°.

[0014] Preferably, the crystalline form A of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles and further has diffraction peaks at one or more of the following 2θ angles: 21.41° ± 0.20°, 21.70° ± 0.20°, 23.00° ± 0.20°, 23.29° ± 0.20°, 24.85° ± 0.20°, 25.27° ± 0.20°, 26.67° ± 0.20°, 27.39° ± 0.20°, 29.53° ± 0.20°, 30.72° ± 0.20°, and 30.79° ± 0.20°.

[0015] In a preferred embodiment, the crystalline form A of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles and may have diffraction peaks at the following 2θ angles: 7.59° ± 0.20°, 9.12° ± 0.20°, 10.09° ± 0.20°, 12.60° ± 0.20°, 15.17° ± 0.20°, 15.96° ± 0.20°, 16.92° ± 0.20°, 17.30° ± 0.20°, 17.60° ± 0.20°, 18.20° ± 0.20°, 19.79° ± 0.20°, 20.90° ± 0.20°, 21.41° ± 0.20°, 21.70° ± 0.20°, 23.00° ± 0.20°, 23.29° ± 0.20°, 24.85° ± 0.20°, 25.27° ± 0.20°, 26.67° ± 0.20°, 27.39° ± 0.20°, 29.53° ± 0.20°, 30.72° ± 0.20°, and 30.79° ± 0.20°.

[0016] In a preferred embodiment, the crystalline form A of the maleate salt of the compound represented by formula (I) has the following interplanar spacings and relative peak height intensities in its X-ray powder diffraction pattern expressed in terms of 2θ angles, where the 2θ error range is ±0.20°:

[0017]

[0018]

[0019] In a preferred embodiment, the crystalline form A of the maleate salt of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles substantially as Figure 56 shown.

[0020] In a preferred embodiment, the crystalline form A of the maleate salt of the compound represented by formula (I) shows a weight loss of 0.3% upon heating from 25 °C to 120 °C in a thermogravimetric analysis.

[0021] In a preferred embodiment, the crystalline form A of the maleate salt of the compound represented by formula (I) has an endothermic peak at 176.7 °C ± 3.0 °C in a differential scanning calorimetry.

[0022] In a preferred embodiment, the differential scanning calorimetry and thermogravimetric analysis of the crystalline form A of the maleate salt of the compound represented by formula (I) are substantially as Figure 57 shown.

[0023] In a preferred embodiment, the maleate salt of the compound represented by formula (I) is

[0024] The third aspect of the present invention further provides a method for preparing a crystalline form of a maleate salt of a compound represented by formula (I), which comprises the following steps: mixing the compound represented by formula (I), maleic acid and a solvent to obtain a mixed solution, and suspending the mixed solution to obtain the crystalline form of the maleate salt of the compound represented by formula (I);

[0025] wherein the solvent is an ether solvent, a mixed solvent of an ether solvent - an alcohol solvent or a mixed solvent of an ether solvent - an alkane solvent.

[0026] In a preferred embodiment, the ether solvent in the ether solvent and the ether solvent in the ether solvent - alkane solvent are independently methyl tert-butyl ether, isopropyl ether and / or tetrahydrofuran.

[0027] In a preferred embodiment, the alkane solvent in the alkane solvent and the alkane solvent in the ether solvent - alkane solvent is cyclohexane.

[0028] In a preferred embodiment, when the solvent is an ether solvent, the ether solvent is methyl tert-butyl ether.

[0029] In a preferred embodiment, when the solvent is a mixed solvent of an ether solvent - an alkane solvent, the ether solvent in the ether solvent - alkane solvent is tetrahydrofuran or isopropyl ether.

[0030] In a preferred embodiment, when the solvent is a mixed solvent of an ether solvent - an alcohol solvent, the alcohol solvent in the ether solvent - alcohol solvent is isopropanol.

[0031] In a preferred embodiment, when the solvent is a mixed solvent of an ether solvent and an alkane solvent, the volume ratio of the ether solvent to the alkane solvent is from 1:1 to 1:10, preferably 1:4.

[0032] In a preferred embodiment, when the solvent is a mixed solvent of an ether solvent and an alkane solvent, the solvent is a mixed solvent of tetrahydrofuran and cyclohexane, for example, a mixed solvent of tetrahydrofuran and cyclohexane with a volume ratio of 1:4.

[0033] In a preferred embodiment, when the solvent is a mixed solvent of an ether solvent and an alcohol solvent, the solvent is a mixed solvent of an ether solvent and an alcohol solvent, for example, a mixed solvent of isopropanol and isopropyl ether with a volume ratio of 1:4.

[0034] In a preferred embodiment, the mass-volume ratio of the compound represented by the formula (I) to the solvent is 10 - 25 mg / mL.

[0035] In a preferred embodiment, the molar ratio of the compound represented by the formula (I) to the maleic acid is from 1:1 to 1:4, preferably 1:1.05, 1:1, 1:2 or 1:4.

[0036] The present invention also provides a crystal form obtained by the preparation method of the crystal form of the maleate salt of the compound represented by the above formula (I).

[0037] In the fourth aspect of the present invention, there is provided a crystal form B of the compound of the formula (I), and its X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 3.76° ± 0.20°, 7.57° ± 0.20°, 9.26° ± 0.20° and 11.38° ± 0.20°.

[0038] In a preferred embodiment, the crystal form B of the compound represented by the formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 15.21° ± 0.20°, 15.96° ± 0.20°, 16.27° ± 0.20° and 17.93° ± 0.20°;

[0039] Preferably, the crystal form B of the compound represented by the formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 18.35° ± 0.20°, 19.00° ± 0.20°, 19.97° ± 0.20°, 20.73° ± 0.20°, 22.92° ± 0.20°, 24.44° ± 0.20°, 28.11° ± 0.20° and 30.75° ± 0.20°.

[0040] In a preferred embodiment, the crystalline form B of the compound represented by formula (I) has X-ray powder diffraction peaks at the following 2θ angles: 3.76° ± 0.20°, 7.57° ± 0.20°, 9.26° ± 0.20°, 11.38° ± 0.20°, 15.21° ± 0.20°, 15.96° ± 0.20°, 16.27° ± 0.20°, 17.93° ± 0.20°, 18.35° ± 0.20°, 19.00° ± 0.20°, 19.97° ± 0.20°, 20.73° ± 0.20°, 22.92° ± 0.20°, 24.44° ± 0.20°, 28.11° ± 0.20°, and 30.75° ± 0.20°.

[0041] In a preferred embodiment, the crystalline form B of the compound represented by formula (I) has an X-ray powder diffraction pattern in terms of 2θ angles substantially as Figure 2 shown.

[0042] In a preferred embodiment, the crystalline form B of the compound represented by formula (I) shows a weight loss of 3.2% upon heating from 25°C to 70°C and a weight loss of 5.4% from 70°C to 180°C in its thermogravimetric analysis.

[0043] In a preferred embodiment, the crystalline form B of the compound represented by formula (I) has two endothermic peaks at 58.5°C ± 3.0°C and 79.9°C ± 3.0°C in its differential scanning calorimetry.

[0044] In a preferred embodiment, the differential scanning calorimetry and thermogravimetric analysis of the crystalline form B of the compound represented by formula (I) are substantially as Figure 3 shown.

[0045] The fifth aspect of the present invention provides a crystalline form C of the compound of formula (I), which has X-ray powder diffraction peaks at the following 2θ angles: 4.11° ± 0.20°, 7.18° ± 0.20°, 8.29° ± 0.20°, and 10.97° ± 0.20°.

[0046] In a preferred embodiment, the crystalline form C of the compound represented by formula (I) has additional diffraction peaks at one or more of the following 2θ angles: 12.43° ± 0.20°, 14.39° ± 0.20°, 14.99° ± 0.20°, 16.62° ± 0.20°, 17.64° ± 0.20°, 18.16° ± 0.20°, and 19.07° ± 0.20°;

[0047] Preferably, for polymorph C of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles further has diffraction peaks at one or more of the following 2θ angles: 19.52° ± 0.20°, 20.86° ± 0.20°, 21.78° ± 0.20°, 22.09° ± 0.20°, 23.31° ± 0.20°, 24.40° ± 0.20°, 25.39° ± 0.20°, 26.30° ± 0.20°, 27.37° ± 0.20°, 28.05° ± 0.20° and 28.40° ± 0.20°.

[0048] In a certain preferred embodiment, for polymorph C of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles may have diffraction peaks at the following 2θ angles: 4.11° ± 0.20°, 7.18° ± 0.20°, 8.29° ± 0.20°, 10.97° ± 0.20°, 12.43° ± 0.20°, 14.39° ± 0.20°, 14.99° ± 0.20°, 16.62° ± 0.20°, 17.64° ± 0.20°, 18.16° ± 0.20°, 19.07° ± 0.20°, 19.52° ± 0.20°, 20.86° ± 0.20°, 21.78° ± 0.20°, 22.09° ± 0.20°, 23.31° ± 0.20°, 24.40° ± 0.20°, 25.39° ± 0.20°, 26.30° ± 0.20°, 27.37° ± 0.20°, 28.05° ± 0.20° and 28.40° ± 0.20°.

[0049] In a certain preferred embodiment, for polymorph C of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles is substantially as Figure 4 shown.

[0050] In a certain preferred embodiment, for polymorph C of the compound represented by formula (I), its thermogravimetric analysis chart shows a weight loss of 4.7% when heated from 25°C to 100°C.

[0051] In a certain preferred embodiment, for polymorph C of the compound represented by formula (I), its differential scanning calorimetry chart has two endothermic peaks at 53.0°C ± 3.0°C and 95.7°C ± 3.0°C.

[0052] In a certain preferred embodiment, for polymorph C of the compound represented by formula (I), its differential scanning heat chart and thermogravimetric analysis chart are substantially as Figure 5 shown.

[0053] The sixth aspect of the present invention provides a crystalline form D of a compound of formula (I), the X-ray powder diffraction pattern of which in terms of 2θ angles has diffraction peaks at the following 2θ angles: 3.89° ± 0.20°, 4.87° ± 0.20°, 5.35° ± 0.20°, 7.08° ± 0.20°, 7.82° ± 0.20°, 15.67° ± 0.20° and 11.73° ± 0.20°.

[0054] In a certain preferred embodiment, the crystalline form D of the compound of formula (I) has an X-ray powder diffraction pattern in terms of 2θ angles and further has diffraction peaks at one or more of the following 2θ angles: 8.01° ± 0.20°, 9.04° ± 0.20°, 9.30° ± 0.20°, 9.51° ± 0.20°, 10.39° ± 0.20°, 11.05° ± 0.20°, 12.76° ± 0.20°, 13.71° ± 0.20°, 15.23° ± 0.20°, 16.14° ± 0.20°, 16.57° ± 0.20°, 16.82° ± 0.20°, 17.21° ± 0.20°, 17.75° ± 0.20° and 18.02° ± 0.20°;

[0055] Preferably, the crystalline form D of the compound of formula (I) has an X-ray powder diffraction pattern in terms of 2θ angles and further has diffraction peaks at one or more of the following 2θ angles: 18.37° ± 0.20°, 18.63° ± 0.20°, 18.67° ± 0.20°, 19.11° ± 0.20°, 19.36° ± 0.20°, 20.01° ± 0.20°, 20.34° ± 0.20°, 20.86° ± 0.20°, 21.23° ± 0.20°, 21.48° ± 0.20°, 22.20° ± 0.20°, 22.71° ± 0.20°, 23.62° ± 0.20°, 23.97° ± 0.20°, 24.48° ± 0.20°, 25.02° ± 0.20°, 26.60° ± 0.20°, 28.40° ± 0.20°, 31.67° ± 0.20°, 32.58° ± 0.20° and 39.89° ± 0.20°.

[0056] In a preferred embodiment, the crystalline form D of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles, which may have diffraction peaks at the following 2θ angles: 3.89° ± 0.20°, 4.87° ± 0.20°, 5.35° ± 0.20°, 7.08° ± 0.20°, 7.82° ± 0.20°, 8.01° ± 0.20°, 9.04° ± 0.20°, 9.30° ± 0.20°, 9.51° ± 0.20°, 10.39° ± 0.20°, 11.05° ± 0.20°, 11.73° ± 0.20°, 12.76° ± 0.20°, 13.71° ± 0.20°, 15.23° ± 0.20°, 15.67° ± 0.20°, 16.14° ± 0.20°, 16.57° ± 0.20°, 16.82° ± 0.20°, 17.21° ± 0.20°, 17.75° ± 0.20°, 18.02° ± 0.20°, 18.37° ± 0.20°, 18.63° ± 0.20°, 18.67° ± 0.20°, 19.11° ± 0.20°, 19.36° ± 0.20°, 20.01° ± 0.20°, 20.34° ± 0.20°, 20.86° ± 0.20°, 21.23° ± 0.20°, 21.48° ± 0.20°, 22.20° ± 0.20°, 22.71° ± 0.20°, 23.62° ± 0.20°, 23.97° ± 0.20°, 24.48° ± 0.20°, 25.02° ± 0.20°, 26.60° ± 0.20°, 28.40° ± 0.20°, 31.67° ± 0.20°, 32.58° ± 0.20° and 39.89° ± 0.20°.

[0057] In a preferred embodiment, the crystalline form D of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles that is substantially as Figure 6 shown.

[0058] In a preferred embodiment, the crystalline form D of the compound represented by formula (I) has a thermogravimetric analysis chart showing a weight loss of 9.6% from 25°C to 75°C and a weight loss of 2.9% from 75°C to 120°C.

[0059] In a preferred embodiment, the crystalline form D of the compound represented by formula (I) has a differential scanning calorimetry chart with two endothermic peaks at 49.7°C ± 3.0°C and 106.1°C ± 3.0°C.

[0060] In a preferred embodiment, the differential scanning calorimetry chart and thermogravimetric analysis chart of the crystalline form D of the compound represented by formula (I) are substantially as Figure 7 shown.

[0061] The seventh aspect of the present invention provides a crystalline form F of a compound of formula (I), the X-ray powder diffraction pattern of which in terms of 2θ angles has diffraction peaks at the following 2θ angles: 3.80° ± 0.20°, 7.70° ± 0.20°, 11.65° ± 0.20° and 15.61° ± 0.20°.

[0062] In a certain preferred embodiment, the crystalline form F of the compound of formula (I) has, in its X-ray powder diffraction pattern in terms of 2θ angles, diffraction peaks at one or more of the following 2θ angles: 5.72° ± 0.20°, 6.46° ± 0.20°, 9.22° ± 0.20°, 9.45° ± 0.20°, 16.04° ± 0.20°, 16.57° ± 0.20°, 17.29° ± 0.20° and 17.95° ± 0.20°;

[0063] Preferably, the crystalline form F of the compound of formula (I) has, in its X-ray powder diffraction pattern in terms of 2θ angles, further diffraction peaks at one or more of the following 2θ angles: 19.07° ± 0.20°, 20.34° ± 0.20°, 20.71° ± 0.20°, 23.54° ± 0.20°, 23.95° ± 0.20°, 24.50° ± 0.20°, 24.98° ± 0.20°, 26.56° ± 0.20°, 27.57° ± 0.20°, 31.61° ± 0.20° and 39.83° ± 0.20°.

[0064] In a certain preferred embodiment, the crystalline form F of the compound of formula (I) may have diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern in terms of 2θ angles: 3.80° ± 0.20°, 5.72° ± 0.20°, 6.46° ± 0.20°, 7.70° ± 0.20°, 9.22° ± 0.20°, 9.45° ± 0.20°, 11.65° ± 0.20°, 15.61° ± 0.20°, 16.04° ± 0.20°, 16.57° ± 0.20°, 17.29° ± 0.20°, 17.95° ± 0.20°, 19.07° ± 0.20°, 20.34° ± 0.20°, 20.71° ± 0.20°, 23.54° ± 0.20°, 23.95° ± 0.20°, 24.50° ± 0.20°, 24.98° ± 0.20°, 26.56° ± 0.20°, 27.57° ± 0.20°, 31.61° ± 0.20° and 39.83° ± 0.20°.

[0065] In a certain preferred embodiment, the crystalline form F of the compound of formula (I) has an X-ray powder diffraction pattern in terms of 2θ angles substantially as Figure 8 shown.

[0066] In a preferred embodiment, for polymorph F of the compound represented by formula (I), the thermogravimetric analysis shows a weight loss of 7.3% when heated from 25 °C to 70 °C, and a weight loss of 1.7% when heated from 70 °C to 120 °C.

[0067] In a preferred embodiment, for polymorph F of the compound represented by formula (I), the differential scanning calorimetry shows two endothermic peaks at 65.1 °C ± 3.0 °C and 86.6 °C ± 3.0 °C.

[0068] In a preferred embodiment, for polymorph F of the compound represented by formula (I), the differential scanning calorimetry and thermogravimetric analysis are substantially as Figure 9 shown.

[0069] The eighth aspect of the present invention provides polymorph A of the hydrochloride salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 5.25° ± 0.20°, 10.62° ± 0.20°, 15.98° ± 0.20°, and 21.39° ± 0.20°; and there is no diffraction peak at 12.04° ± 0.20°.

[0070] In a preferred embodiment, for polymorph A of the hydrochloride salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles further has diffraction peaks at one or more of the following 2θ angles: 24.75° ± 0.20°, 32.39° ± 0.20°, and 37.98° ± 0.20°.

[0071] In a preferred embodiment, for polymorph A of the hydrochloride salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles may have diffraction peaks at the following 2θ angles: 5.25° ± 0.20°, 10.62° ± 0.20°, 15.98° ± 0.20°, 21.39° ± 0.20°, 24.75° ± 0.20°, 32.39° ± 0.20°, and 37.98° ± 0.20°.

[0072] In a preferred embodiment, for polymorph A of the hydrochloride salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles is substantially as Figure 11 shown.

[0073] In a preferred embodiment, for polymorph A of the hydrochloride salt of the compound represented by formula (I), the thermogravimetric analysis shows a weight loss of 4.0% when heated from 25 °C to 140 °C.

[0074] In a preferred embodiment, the crystalline form A of the hydrochloride salt of the compound represented by formula (I) has two endothermic peaks at 121.9 ± 3 °C and 176.1 ± 3 °C in its differential scanning calorimetry (DSC) curve.

[0075] In a preferred embodiment, the differential scanning calorimetry (DSC) curve and thermogravimetric analysis (TGA) curve of the crystalline form A of the hydrochloride salt of the compound represented by formula (I) are substantially as Figure 12 shown.

[0076] In a preferred embodiment, in the crystalline form A of the hydrochloride salt of the compound represented by formula (I), the hydrochloride salt is

[0077]

[0078] The ninth aspect of the present invention provides a crystalline form B of the hydrochloride salt of the compound represented by formula (I), which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern expressed in terms of 2θ angle: 5.12° ± 0.20°, 10.37° ± 0.20°, 12.04° ± 0.20°, 15.67° ± 0.20° and 18.20° ± 0.20°.

[0079] In a preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B of the hydrochloride salt of the compound represented by formula (I), expressed in terms of 2θ angle, further has diffraction peaks at one or more of the following 2θ angles: 9.10° ± 0.20°, 9.51° ± 0.20° and 13.86° ± 0.20°;

[0080] Preferably, the X-ray powder diffraction pattern of the crystalline form B of the hydrochloride salt of the compound represented by formula (I), expressed in terms of 2θ angle, further has diffraction peaks at one or more of the following 2θ angles: 16.59° ± 0.20°, 18.88° ± 0.20°, 19.52° ± 0.20°, 20.45° ± 0.20°, 20.96° ± 0.20° and 21.56° ± 0.20°.

[0081] In a preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B of the hydrochloride salt of the compound represented by formula (I), expressed in terms of 2θ angle, may have diffraction peaks at the following 2θ angles: 5.12° ± 0.20°, 9.10° ± 0.20°, 9.51° ± 0.20°, 10.37° ± 0.20°, 12.04° ± 0.20°, 13.86° ± 0.20°, 15.67° ± 0.20°, 16.59° ± 0.20°, 18.20° ± 0.20°, 18.88° ± 0.20°, 19.52° ± 0.20°, 20.45° ± 0.20°, 20.96° ± 0.20° and 21.56° ± 0.20°.

[0082] In a preferred embodiment, the crystalline form B of the hydrochloride salt of the compound of formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles substantially as Figure 14 shown.

[0083] In a preferred embodiment, the crystalline form B of the hydrochloride salt of the compound of formula (I) shows a weight loss of 2.9% upon heating from 25 °C to 100 °C in the thermogravimetric analysis.

[0084] In a preferred embodiment, the crystalline form B of the hydrochloride salt of the compound of formula (I) has three endothermic peaks at 78.1 °C ± 3 °C, 133.7 °C ± 3 °C and 167.5 °C ± 3 °C in the differential scanning calorimetry.

[0085] In a preferred embodiment, the differential scanning calorimetry and thermogravimetric analysis of the crystalline form B of the hydrochloride salt of the compound of formula (I) are substantially as Figure 15 shown.

[0086] In a preferred embodiment, in the crystalline form B of the hydrochloride salt of the compound of formula (I), the hydrochloride salt is

[0087]

[0088] The tenth aspect of the present invention provides a crystalline form A of the p-toluenesulfonate salt of the compound of formula (I), which has diffraction peaks at the following 2θ angles in the X-ray powder diffraction pattern expressed in terms of 2θ angles: 4.52° ± 0.20°, 7.37° ± 0.20°, 10.99° ± 0.20°, 12.60° ± 0.20° and 18.28° ± 0.20°.

[0089] In a preferred embodiment, the X-ray powder diffraction pattern expressed in terms of 2θ angles of the crystalline form A of the p-toluenesulfonate salt of the compound of formula (I) further has diffraction peaks at one or more of the following 2θ angles: 5.95° ± 0.20°, 7.59° ± 0.20°, 9.06° ± 0.20°, 14.72° ± 0.20°, 15.03° ± 0.20°, 15.28° ± 0.20°, 16.00° ± 0.20°, 16.74° ± 0.20°, 17.85° ± 0.20°, 18.30° ± 0.20°, 18.59° ± 0.20°, 19.11° ± 0.20°, 19.77° ± 0.20°, 20.40° ± 0.20°, 20.78° ± 0.20°, 21.39° ± 0.20° and 22.07° ± 0.20°;

[0090] Preferably, the crystal form A of the p-toluenesulfonate salt of the compound represented by the formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle and further has diffraction peaks at one or more of the following 2θ angles: 22.75° ± 0.20°, 23.31° ± 0.20°, 23.64° ± 0.20°, 24.48° ± 0.20°, 25.12° ± 0.20°, 25.88° ± 0.20°, 26.07° ± 0.20°, 26.26° ± 0.20°, 26.93° ± 0.20°, 27.33° ± 0.20°, 27.64° ± 0.20°, 28.52° ± 0.20°, 28.91° ± 0.20°, 29.10° ± 0.20°, 29.53° ± 0.20°, 31.42° ± 0.20°, 32.00° ± 0.20°, 32.83° ± 0.20°, 33.77° ± 0.20°, 35.94° ± 0.20°, 36.78° ± 0.20° and 39.50° ± 0.20°.

[0091] In a preferred embodiment, the X-ray powder diffraction pattern of crystalline form A of the p-toluenesulfonate of the compound represented by formula (I), expressed in terms of 2θ angles, may have diffraction peaks at the following 2θ angles: 4.52° ± 0.20°, 5.95° ± 0.20°, 7.37° ± 0.20°, 7.59° ± 0.20°, 9.06° ± 0.20°, 10.99° ± 0.20°, 12.60° ± 0.20°, 14.72° ± 0.20°, 15.03° ± 0.20°, 15.28° ± 0.20°, 16.00° ± 0.20°, 16.74° ± 0.20°, 17.85° ± 0.20°, 18.28° ± 0.20°, 18.30° ± 0.20°, 18.59° ± 0.20°, 19.11° ± 0.20°, 19.77° ± 0.20°, 20.40° ± 0.20°, 20.78° ± 0.20°, 21.39° ± 0.20°, 22.07° ± 0.20°, 22.75° ± 0.20°, 23.31° ± 0.20°, 23.64° ± 0.20°, 24.48° ± 0.20°, 25.12° ± 0.20°, 25.88° ± 0.20°, 26.07° ± 0.20°, 26.26° ± 0.20°, 26.93° ± 0.20°, 27.33° ± 0.20°, 27.64° ± 0.20°, 28.52° ± 0.20°, 28.91° ± 0.20°, 29.10° ± 0.20°, 29.53° ± 0.20°, 31.42° ± 0.20°, 32.00° ± 0.20°, 32.83° ± 0.20°, 33.77° ± 0.20°, 35.94° ± 0.20°, 36.78° ± 0.20° and 39.50° ± 0.20°.

[0092] In a preferred embodiment, the X-ray powder diffraction pattern of crystalline form A of the p-toluenesulfonate of the compound represented by formula (I) is substantially as Figure 17 shown.

[0093] In a preferred embodiment, the thermogravimetric analysis of crystalline form A of the p-toluenesulfonate of the compound represented by formula (I) shows a weight loss of 1.1% when heated from 25°C to 70°C and a weight loss of 2.1% during the process of heating from 70°C to 150°C.

[0094] In a preferred embodiment, the differential scanning calorimetry of crystalline form A of the p-toluenesulfonate of the compound represented by formula (I) has two endothermic peaks at 115.0 ± 3°C and 157.3 ± 3°C.

[0095] In a certain preferred embodiment, the crystal form A of the p-toluenesulfonate salt of the compound represented by formula (I) has a differential scanning calorimetry (DSC) thermogram and a thermogravimetric analysis (TGA) thermogram substantially as Figure 18 shown.

[0096] In a certain preferred embodiment, in the crystal form A of the p-toluenesulfonate salt of the compound represented by formula (I), the p-toluenesulfonate salt is

[0097] The eleventh aspect of the present invention provides a crystal form A of the hydrobromide salt of the compound represented by formula (I), the X-ray powder diffraction pattern of which, expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 5.33° ± 0.20°, 10.64° ± 0.20°, 16.00° ± 0.20° and 21.41° ± 0.20°; and, there is no diffraction peak at least at one of 12.15° ± 0.20° and 14.00° ± 0.20°.

[0098] In a certain preferred embodiment, the crystal form A of the hydrobromide salt of the compound represented by formula (I), the X-ray powder diffraction pattern of which, expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 18.68° ± 0.20°, 24.71° ± 0.20°, 26.38° ± 0.20°, 26.87° ± 0.20° and 32.35° ± 0.20°.

[0099] In a certain preferred embodiment, the crystal form A of the hydrobromide salt of the compound represented by formula (I), the X-ray powder diffraction pattern of which, expressed in 2θ angles, may have diffraction peaks at the following 2θ angles: 5.33° ± 0.20°, 10.64° ± 0.20°, 16.00° ± 0.20°, 18.68° ± 0.20°, 21.41° ± 0.20°, 24.71° ± 0.20°, 26.38° ± 0.20°, 26.87° ± 0.20° and 32.35° ± 0.20°.

[0100] In a certain preferred embodiment, the crystal form A of the hydrobromide salt of the compound represented by formula (I) has a differential scanning calorimetry (DSC) thermogram substantially as Figure 20 shown.

[0101] In a certain preferred embodiment, the crystal form A of the hydrobromide salt of the compound represented by formula (I) has a thermogravimetric analysis (TGA) thermogram showing a weight loss of 3.0% when heated from 25°C to 140°C.

[0102] In a certain preferred embodiment, the crystal form A of the hydrobromide salt of the compound represented by formula (I) has two endothermic peaks in the differential scanning calorimetry (DSC) thermogram at 133.5 ± 3°C and 188.9 ± 3°C.

[0103] In a preferred embodiment, the crystal form A of the hydrobromide salt of the compound represented by formula (I) has a differential scanning calorimetry (DSC) thermogram and a thermogravimetric analysis (TGA) thermogram substantially as Figure 21 shown.

[0104] In a preferred embodiment, in the crystal form A of the hydrobromide salt of the compound represented by formula (I), the hydrobromide salt is

[0105]

[0106] The twelfth aspect of the present invention provides a crystal form B of the hydrobromide salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in terms of 2θ angle has diffraction peaks at the following 2θ angles: 5.27° ± 0.20°, 10.50° ± 0.20°, 12.15° ± 0.20°, 14.00° ± 0.20°, 15.75° ± 0.20° and 21.02° ± 0.20°.

[0107] In a preferred embodiment, the crystal form B of the hydrobromide salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in terms of 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 9.63° ± 0.20°, 16.82° ± 0.20°, 18.33° ± 0.20°, 18.92° ± 0.20°, 19.48° ± 0.20°, 20.61° ± 0.20°, 22.67° ± 0.20° and 22.92° ± 0.20°.

[0108] Preferably, the crystal form B of the hydrobromide salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in terms of 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 24.40° ± 0.20°, 25.93° ± 0.20°, 26.38° ± 0.20°, 27.04° ± 0.20°, 27.57° ± 0.20°, 27.96° ± 0.20°, 29.04° ± 0.20°, 29.53° ± 0.20°, 30.40° ± 0.20°, 30.91° ± 0.20°, 31.78° ± 0.20°, 33.53° ± 0.20°, 34.45° ± 0.20° and 37.13° ± 0.20°.

[0109] In a preferred embodiment, for polymorph B of the hydrobromide salt of the compound represented by formula (I), the X-ray powder diffraction pattern in terms of 2θ angles may have diffraction peaks at the following 2θ angles: 5.27° ± 0.20°, 9.63° ± 0.20°, 10.50° ± 0.20°, 12.15° ± 0.20°, 14.00° ± 0.20°, 15.75° ± 0.20°, 16.82° ± 0.20°, 18.33° ± 0.20°, 18.92° ± 0.20°, 19.48° ± 0.20°, 20.61° ± 0.20°, 21.02° ± 0.20°, 22.67° ± 0.20°, 22.92° ± 0.20°, 24.40° ± 0.20°, 25.93° ± 0.20°, 26.38° ± 0.20°, 27.04° ± 0.20°, 27.57° ± 0.20°, 27.96° ± 0.20°, 29.04° ± 0.20°, 29.53° ± 0.20°, 30.40° ± 0.20°, 30.91° ± 0.20°, 31.78° ± 0.20°, 33.53° ± 0.20°, 34.45° ± 0.20°, and 37.13° ± 0.20°.

[0110] In a preferred embodiment, for polymorph B of the hydrobromide salt of the compound represented by formula (I), the X-ray powder diffraction pattern in terms of 2θ angles is substantially as Figure 23 shown.

[0111] In a preferred embodiment, for polymorph B of the hydrobromide salt of the compound represented by formula (I), the thermogravimetric analysis chart shows a weight loss of 3.8% when heated from 25°C to 140°C.

[0112] In a preferred embodiment, for polymorph B of the hydrobromide salt of the compound represented by formula (I), the differential scanning calorimetry chart has three endothermic peaks at 80.3°C ± 3°C, 159.7 ± 3°C, and 177.2 ± 3°C.

[0113] In a preferred embodiment, for polymorph B of the hydrobromide salt of the compound represented by formula (I), the differential scanning calorimetry chart and the thermogravimetric analysis chart are substantially as Figure 24 shown.

[0114] In a preferred embodiment, in polymorph B of the hydrobromide salt of the compound represented by formula (I), the hydrobromide salt is

[0115]

[0116] The thirteenth aspect of the present invention provides polymorph A of the phosphate salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in terms of 2θ angle has diffraction peaks at the following 2θ angles: 14.33° ± 0.20°, 15.32° ± 0.20°, 17.99° ± 0.20° and 21.37° ± 0.20°.

[0117] In a certain preferred embodiment, the polymorph A of the phosphate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ angle, further has diffraction peaks at one or more of the following 2θ angles: 9.04° ± 0.20°, 10.95° ± 0.20°, 13.09° ± 0.20°, 16.29° ± 0.20°, 18.82° ± 0.20°, 19.60° ± 0.20°, 20.82° ± 0.20°, 21.78° ± 0.20° and 22.18° ± 0.20°.

[0118] Preferably, the polymorph A of the phosphate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ angle, further has diffraction peaks at one or more of the following 2θ angles: 22.63° ± 0.20°, 22.94° ± 0.20°, 24.11° ± 0.20°, 25.84° ± 0.20°, 26.79° ± 0.20°, 27.10° ± 0.20°, 27.61° ± 0.20°, 28.32° ± 0.20°, 28.64° ± 0.20°, 29.39° ± 0.20°, 30.79° ± 0.20° and 31.43° ± 0.20°.

[0119] In a certain preferred embodiment, the polymorph A of the phosphate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ angle, may have diffraction peaks at the following 2θ angles: 9.04° ± 0.20°, 10.95° ± 0.20°, 13.09° ± 0.20°, 14.33° ± 0.20°, 15.32° ± 0.20°, 16.29° ± 0.20°, 17.99° ± 0.20°, 18.82° ± 0.20°, 19.60° ± 0.20°, 20.82° ± 0.20°, 21.37° ± 0.20°, 21.78° ± 0.20°, 22.18° ± 0.20°, 22.63° ± 0.20°, 22.94° ± 0.20°, 24.11° ± 0.20°, 25.84° ± 0.20°, 26.79° ± 0.20°, 27.10° ± 0.20°, 27.61° ± 0.20°, 28.32° ± 0.20°, 28.64° ± 0.20°, 29.39° ± 0.20°, 30.79° ± 0.20° and 31.43° ± 0.20°.

[0120] In a certain preferred embodiment, the crystalline form A of the phosphate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles substantially as Figure 26 shown.

[0121] In a certain preferred embodiment, the crystalline form A of the phosphate of the compound represented by formula (I) shows a weight loss of 1.1% when heated from 25 °C to 100 °C in a thermogravimetric analysis graph.

[0122] In a certain preferred embodiment, the crystalline form A of the phosphate of the compound represented by formula (I) has two endothermic peaks at 36.8 ± 3 °C and 177.4 ± 3 °C in a differential scanning calorimetry graph.

[0123] In a certain preferred embodiment, the differential scanning calorimetry graph and thermogravimetric analysis graph of the crystalline form A of the phosphate of the compound represented by formula (I) are substantially as Figure 27 shown.

[0124] In a certain preferred embodiment, in the crystalline form A of the phosphate of the compound represented by formula (I), the phosphate is

[0125]

[0126] The fourteenth aspect of the present invention provides a crystalline form B of a phosphate of a compound represented by formula (I), which has diffraction peaks at the following 2θ angles in an X-ray powder diffraction pattern expressed in terms of 2θ angles: 10.23° ± 0.20°, 10.62° ± 0.20°, 13.30° ± 0.20°, 16.94° ± 0.20°, and 18.92° ± 0.20°.

[0127] In a certain preferred embodiment, the crystalline form B of the phosphate of the compound represented by formula (I) has diffraction peaks at one or more of the following 2θ angles in an X-ray powder diffraction pattern expressed in terms of 2θ angles: 8.54° ± 0.20°, 16.43° ± 0.20°, 17.30° ± 0.20°, and 20.88° ± 0.20°.

[0128] Preferably, the crystalline form B of the phosphate of the compound represented by formula (I) has diffraction peaks at one or more of the following 2θ angles in an X-ray powder diffraction pattern expressed in terms of 2θ angles: 21.41° ± 0.20°, 23.52° ± 0.20°, 24.98° ± 0.20°, 25.43° ± 0.20°, 26.13° ± 0.20°, 26.75° ± 0.20°, 27.55° ± 0.20°, 29.24° ± 0.20°, and 34.86° ± 0.20°.

[0129] In a certain preferred embodiment, for polymorph B of the phosphate of the compound represented by formula (I), the X-ray powder diffraction pattern in terms of 2θ angle may have diffraction peaks at the following 2θ angles: 8.54° ± 0.20°, 10.23° ± 0.20°, 10.62° ± 0.20°, 13.30° ± 0.20°, 16.43° ± 0.20°, 16.94° ± 0.20°, 17.30° ± 0.20°, 18.92° ± 0.20°, 20.88° ± 0.20°, 21.41° ± 0.20°, 23.52° ± 0.20°, 24.98° ± 0.20°, 25.43° ± 0.20°, 26.13° ± 0.20°, 26.75° ± 0.20°, 27.55° ± 0.20°, 29.24° ± 0.20° and 34.86° ± 0.20°.

[0130] In a certain preferred embodiment, for polymorph B of the phosphate of the compound represented by formula (I), the X-ray powder diffraction pattern in terms of 2θ angle is substantially as Figure 29 shown.

[0131] In a certain preferred embodiment, for polymorph B of the phosphate of the compound represented by formula (I), its thermogravimetric analysis chart shows a weight loss of 2.6% when heated from 25°C to 60°C, and a weight loss of 2.2% during the process of heating from 60°C to 120°C.

[0132] In a certain preferred embodiment, for polymorph B of the phosphate of the compound represented by formula (I), its differential scanning calorimetry chart has three endothermic peaks at 48.0°C ± 3°C, 113.7 ± 3°C and 139.1 ± 3°C.

[0133] In a certain preferred embodiment, for polymorph B of the phosphate of the compound represented by formula (I), its differential scanning calorimetry chart and thermogravimetric analysis chart are substantially as Figure 30 shown.

[0134] In a certain preferred embodiment, in polymorph B of the phosphate of the compound represented by formula (I), the phosphate is

[0135]

[0136] The fifteenth aspect of the present invention provides a crystalline form C of the phosphate of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 8.01° ± 0.20°, 8.89° ± 0.20°, 10.58° ± 0.20°, 14.10° ± 0.20°, 15.07° ± 0.20°, 16.31° ± 0.20°, 16.94° ± 0.20°, 17.54° ± 0.20°, 18.55° ± 0.20°, 21.89° ± 0.20° and 22.82° ± 0.20°.

[0137] In a certain preferred embodiment, the crystalline form C of the phosphate of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 20.45° ± 0.20° and 25.70° ± 0.20°.

[0138] In a certain preferred embodiment, the crystalline form C of the phosphate of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, may have diffraction peaks at the following 2θ angles: 8.01° ± 0.20°, 8.89° ± 0.20°, 10.58° ± 0.20°, 14.10° ± 0.20°, 15.07° ± 0.20°, 16.31° ± 0.20°, 16.94° ± 0.20°, 17.54° ± 0.20°, 18.55° ± 0.20°, 20.45° ± 0.20°, 21.89° ± 0.20°, 22.82° ± 0.20° and 25.70° ± 0.20°.

[0139] In a certain preferred embodiment, the crystalline form C of the phosphate of the compound represented by formula (I), its X-ray powder diffraction pattern is substantially as Figure 32 shown.

[0140] In a certain preferred embodiment, for the crystalline form C of the phosphate of the compound represented by formula (I), its thermogravimetric analysis diagram shows a weight loss of 1.9% when heated from 25°C to 120°C.

[0141] In a certain preferred embodiment, the crystalline form C of the phosphate of the compound represented by formula (I), its differential scanning calorimetry diagram has two endothermic peaks at 60.3 ± 3°C and 158.0 ± 3°C.

[0142] In a certain preferred embodiment, the crystalline form C of the phosphate of the compound represented by formula (I), its differential scanning calorimetry diagram and thermogravimetric analysis diagram are substantially as Figure 33 shown.

[0143] In a certain preferred embodiment, in the crystalline form C of the phosphate of the compound represented by formula (I), the phosphate is

[0144]

[0145] The sixteenth aspect of the present invention provides crystal form A of the oxalate of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in 2θ angle has diffraction peaks at the following 2θ angles: 4.98±0.20°, 5.04±0.20°, 10.72°±0.20° and 18.68°±0.20°.

[0146] In a certain preferred embodiment, for crystal form A of the oxalate of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 13.50°±0.20°, 17.73°±0.20° and 18.32°±0.20°.

[0147] Preferably, for crystal form A of the oxalate of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 19.09°±0.20°, 19.46°±0.20°, 20.51°±0.20°, 24.42°±0.20°, 26.03°±0.20°, 26.61°±0.20° and 27.04°±0.20°.

[0148] In a certain preferred embodiment, for crystal form A of the oxalate of the compound represented by formula (I), its X-ray powder diffraction pattern may have diffraction peaks at the following 2θ angles: 4.98±0.20°, 5.04±0.20°, 10.72°±0.20°, 13.50°±0.20°, 17.73°±0.20°, 18.32°±0.20°, 18.68°±0.20°, 19.09°±0.20°, 19.46°±0.20°, 20.51°±0.20°, 24.42±0.20°, 26.03°±0.20°, 26.61°±0.20° and 27.04°±0.20°.

[0149] In a certain preferred embodiment, for crystal form A of the oxalate of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angle is substantially as Figure 35 shown.

[0150] In a certain preferred embodiment, for crystal form A of the oxalate of the compound represented by formula (I), its thermogravimetric analysis chart shows that the weight loss from 25°C to 100°C is 1.2%.

[0151] In a preferred embodiment, the crystalline form A of the oxalate of the compound represented by formula (I) has two endothermic peaks in the differential scanning calorimetry (DSC) curve at 84.7 ± 3 °C and 154.0 ± 3 °C.

[0152] In a preferred embodiment, the crystalline form A of the oxalate of the compound represented by formula (I) has a differential scanning calorimetry (DSC) curve and a thermogravimetric analysis (TGA) curve substantially as Figure 36 shown.

[0153] The seventeenth aspect of the present invention provides a crystalline form B of the oxalate of the compound represented by formula (I), the X-ray powder diffraction pattern of which in terms of 2θ angle has diffraction peaks at the following 2θ angles: 4.96° ± 0.20°, 11.47° ± 0.20°, 12.35° ± 0.20°, 14.97° ± 0.20° and 19.11° ± 0.20°.

[0154] In a preferred embodiment, the X-ray powder diffraction pattern of the crystalline form B of the oxalate of the compound represented by formula (I) in terms of 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 9.45° ± 0.20°, 9.98° ± 0.20°, 15.61° ± 0.20°, 18.47° ± 0.20° and 20.06° ± 0.20°.

[0155] Preferably, the X-ray powder diffraction pattern of the crystalline form B of the oxalate of the compound represented by formula (I) in terms of 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 20.47° ± 0.20°, 21.37° ± 0.20°, 23.91° ± 0.20°, 24.30° ± 0.20°, 25.04° ± 0.20°, 26.21° ± 0.20°, 27.18° ± 0.20°, 31.67° ± 0.20°, 34.97° ± 0.20° and 40.01° ± 0.20°.

[0156] In a certain preferred embodiment, the polymorph B of the oxalate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle, and diffraction peaks can be present at the following 2θ angles: 4.96° ± 0.20°, 9.45° ± 0.20°, 9.98° ± 0.20°, 11.47° ± 0.20°, 12.35° ± 0.20°, 14.97° ± 0.20°, 15.61° ± 0.20°, 18.47° ± 0.20°, 19.11° ± 0.20°, 20.06° ± 0.20°, 20.47° ± 0.20°, 21.37° ± 0.20°, 23.91° ± 0.20°, 24.30° ± 0.20°, 25.04° ± 0.20°, 26.21° ± 0.20°, 27.18° ± 0.20°, 31.67° ± 0.20°, 34.97° ± 0.20°, and 40.01° ± 0.20°.

[0157] In a certain preferred embodiment, the polymorph B of the oxalate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle substantially as Figure 38 shown.

[0158] In a certain preferred embodiment, the polymorph B of the oxalate of the compound represented by formula (I) shows a weight loss of 3.0% upon heating from 25°C to 100°C in its thermogravimetric analysis graph.

[0159] In a certain preferred embodiment, the polymorph B of the oxalate of the compound represented by formula (I) has three endothermic peaks at 71.6°C ± 3°C, 149.5 ± 3°C, and 156.0 ± 3°C in its differential scanning calorimetry graph.

[0160] In a certain preferred embodiment, the differential scanning calorimetry graph and thermogravimetric analysis graph of the polymorph B of the oxalate of the compound represented by formula (I) are substantially as Figure 39 shown.

[0161] The eighteenth aspect of the present invention provides a polymorph C of the oxalate of the compound represented by formula (I), which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern expressed in terms of 2θ angle: 4.81° ± 0.20°, 9.76° ± 0.20°, 11.51° ± 0.20°, 14.99° ± 0.20°, 19.13° ± 0.20°, 19.99° ± 0.20°, 24.30° ± 0.20°, and 26.11° ± 0.20°.

[0162] In a certain preferred embodiment, the polymorph C of the oxalate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle substantially as Figure 41 shown.

[0163] In a preferred embodiment, the crystal form C of the oxalate of the compound represented by formula (I) shows a weight loss of 3.5% when heated from 25 °C to 130 °C in the thermogravimetric analysis graph.

[0164] In a preferred embodiment, the crystal form C of the oxalate of the compound represented by formula (I) has two endothermic peaks at 67.8 ± 3 °C and 150.6 ± 3 °C in the differential scanning calorimetry graph.

[0165] In a preferred embodiment, the differential scanning calorimetry graph and the thermogravimetric analysis graph of the crystal form C of the oxalate of the compound represented by formula (I) are substantially as Figure 42 shown.

[0166] The nineteenth aspect of the present invention provides a crystal form D of the oxalate of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 4.57° ± 0.20°, 17.32° ± 0.20°, 18.18° ± 0.20° and 22.98° ± 0.20°.

[0167] In a preferred embodiment, the X-ray powder diffraction pattern expressed in 2θ angles of the crystal form D of the oxalate of the compound represented by formula (I) further has diffraction peaks at one or more of the following 2θ angles: 9.06° ± 0.20°, 11.05° ± 0.20°, 13.57° ± 0.20°, 14.31° ± 0.20°, 16.68° ± 0.20°, 18.88° ± 0.20°, 19.58° ± 0.20°, 20.10° ± 0.20° and 21.44° ± 0.20°.

[0168] Preferably, the X-ray powder diffraction pattern expressed in 2θ angles of the crystal form D of the oxalate of the compound represented by formula (I) further has diffraction peaks at one or more of the following 2θ angles: 22.36° ± 0.20°, 24.42° ± 0.20°, 24.63° ± 0.20°, 25.12° ± 0.20°, 26.25° ± 0.20°, 27.53° ± 0.20°, 28.27° ± 0.20°, 29.06° ± 0.20°, 30.52° ± 0.20° and 32.10° ± 0.20°.

[0169] In a preferred embodiment, the polymorph D of the oxalate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles and may have diffraction peaks at the following 2θ angles: 4.57° ± 0.20°, 9.06° ± 0.20°, 11.05° ± 0.20°, 13.57° ± 0.20°, 14.31° ± 0.20°, 16.68° ± 0.20°, 17.32° ± 0.20°, 18.18° ± 0.20°, 18.88° ± 0.20°, 19.58° ± 0.20°, 20.10° ± 0.20°, 21.44° ± 0.20°, 22.36° ± 0.20°, 22.98° ± 0.20°, 24.42° ± 0.20°, 24.63° ± 0.20°, 25.12° ± 0.20°, 26.25° ± 0.20°, 27.53° ± 0.20°, 28.27° ± 0.20°, 29.06° ± 0.20°, 30.52° ± 0.20° and 32.10° ± 0.20°.

[0170] In a preferred embodiment, the polymorph D of the oxalate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angles substantially as Figure 44 shown.

[0171] In a preferred embodiment, the polymorph D of the oxalate of the compound represented by formula (I) has a thermogravimetric analysis chart showing a weight loss of 6.8% when heated from 25°C to 110°C.

[0172] In a preferred embodiment, the polymorph D of the oxalate of the compound represented by formula (I) has a differential scanning calorimetry chart with two endothermic peaks at 64.9 ± 3°C and 118.6 ± 3°C.

[0173] In a preferred embodiment, the differential scanning calorimetry chart and thermogravimetric analysis chart of the polymorph D of the oxalate of the compound represented by formula (I) are substantially as Figure 45 shown.

[0174] The twentieth aspect of the present invention provides a polymorph A of the 2-naphthalenesulfonate of the compound represented by formula (I), which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern expressed in terms of 2θ angles: 7.06° ± 0.20°, 17.01° ± 0.20°, 18.37° ± 0.20°, 22.42° ± 0.20° and 24.61° ± 0.20°.

[0175] In a certain preferred embodiment, the X-ray powder diffraction pattern of crystalline form A of the 2-naphthalenesulfonate of the compound represented by formula (I), in terms of 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 8.97° ± 0.20°, 10.50° ± 0.20°, 10.93° ± 0.20°, 11.80° ± 0.20°, 14.72° ± 0.20°, 15.56° ± 0.20°, 17.99° ± 0.20°, and 18.86° ± 0.20°.

[0176] Preferably, the X-ray powder diffraction pattern of crystalline form A of the 2-naphthalenesulfonate of the compound represented by formula (I), in terms of 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 19.31° ± 0.20°, 20.10° ± 0.20°, 20.78° ± 0.20°, 21.93° ± 0.20°, 23.72° ± 0.20°, 25.14° ± 0.20°, 25.84° ± 0.20°, 27.43° ± 0.20°, and 28.56° ± 0.20°.

[0177] In a certain preferred embodiment, the X-ray powder diffraction pattern of crystalline form A of the 2-naphthalenesulfonate of the compound represented by formula (I), in terms of 2θ angles, may have diffraction peaks at the following 2θ angles: 7.06° ± 0.20°, 8.97° ± 0.20°, 10.50° ± 0.20°, 10.93° ± 0.20°, 11.80° ± 0.20°, 14.72° ± 0.20°, 15.56° ± 0.20°, 17.01° ± 0.20°, 17.99° ± 0.20°, 18.37° ± 0.20°, 18.86° ± 0.20°, 19.31° ± 0.20°, 20.10° ± 0.20°, 20.78° ± 0.20°, 21.93° ± 0.20°, 22.42° ± 0.20°, 23.72° ± 0.20°, 24.61° ± 0.20°, 25.14° ± 0.20°, 25.84° ± 0.20°, 27.43° ± 0.20°, and 28.56° ± 0.20°.

[0178] In a certain preferred embodiment, the X-ray powder diffraction pattern of crystalline form A of the 2-naphthalenesulfonate of the compound represented by formula (I), in terms of 2θ angles, is substantially as Figure 47 shown.

[0179] In a certain preferred embodiment, the thermogravimetric analysis diagram of crystalline form A of the 2-naphthalenesulfonate of the compound represented by formula (I) shows a weight loss of 3.3% when heated from 25°C to 100°C and a weight loss of 4.3% when heated from 100°C to 170°C.

[0180] In a preferred embodiment, the polymorph A of the 2-naphthalenesulfonate of the compound represented by formula (I) has three endothermic peaks in its differential scanning calorimetry (DSC) curve at 51.5 ± 3 °C, 117.8 ± 3 °C and 125.1 ± 3 °C.

[0181] In a preferred embodiment, the polymorph A of the 2-naphthalenesulfonate of the compound represented by formula (I) has a DSC curve and a thermogravimetric analysis (TGA) curve substantially as Figure 48 shown.

[0182] In a preferred embodiment of the polymorph A of the 2-naphthalenesulfonate of the compound represented by formula (I), the 2-naphthalenesulfonate is

[0183]

[0184] A twenty-first aspect of the present invention provides a polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I), the X-ray powder diffraction pattern of which in terms of 2θ angle has diffraction peaks at the following 2θ angles: 5.22° ± 0.20°, 5.76° ± 0.20°, 6.71° ± 0.20°, 11.12° ± 0.20°, 15.67° ± 0.20°, 16.06° ± 0.20°, 16.57° ± 0.20°, 18.18° ± 0.20°, 19.17° ± 0.20° and 21.41° ± 0.20°.

[0185] In a preferred embodiment, the X-ray powder diffraction pattern of the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I) in terms of 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 7.12° ± 0.20°, 9.10° ± 0.20°, 10.42° ± 0.20°, 10.75° ± 0.20°, 15.36° ± 0.20°, 17.79° ± 0.20° and 18.76° ± 0.20°.

[0186] Preferably, the X-ray powder diffraction pattern of the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I) in terms of 2θ angle further has diffraction peaks at one or more of the following 2θ angles: 20.43° ± 0.20°, 21.70° ± 0.20°, 22.36° ± 0.20°, 22.63° ± 0.20°, 23.37° ± 0.20°, 24.32° ± 0.20°, 24.55° ± 0.20°, 25.84° ± 0.20°, 26.91° ± 0.20°, 27.72° ± 0.20°, 28.46° ± 0.20° and 30.17° ± 0.20°.

[0187] In a preferred embodiment, the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle, which may have diffraction peaks at the following 2θ angles: 5.22° ± 0.20°, 5.76° ± 0.20°, 6.71° ± 0.20°, 7.12° ± 0.20°, 9.10° ± 0.20°, 10.42° ± 0.20°, 10.75° ± 0.20°, 11.12° ± 0.20°, 15.36° ± 0.20°, 15.67° ± 0.20°, 16.06° ± 0.20°, 16.57° ± 0.20°, 17.79° ± 0.20°, 18.18° ± 0.20°, 18.76° ± 0.20°, 19.17° ± 0.20°, 20.43° ± 0.20°, 21.41° ± 0.20°, 21.70° ± 0.20°, 22.36° ± 0.20°, 22.63° ± 0.20°, 23.37° ± 0.20°, 24.32° ± 0.20°, 24.55° ± 0.20°, 25.84° ± 0.20°, 26.91° ± 0.20°, 27.72° ± 0.20°, 28.46° ± 0.20° and 30.17° ± 0.20°.

[0188] In a preferred embodiment, the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle that is substantially as Figure 50 shown.

[0189] In a preferred embodiment, the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I) has a thermogravimetric analysis chart showing a weight loss of 4.3% when heated from 25°C to 130°C.

[0190] In a preferred embodiment, the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I) has a differential scanning calorimetry chart with an endothermic peak at 90.5 ± 3°C.

[0191] In a preferred embodiment, the differential scanning calorimetry chart and thermogravimetric analysis chart of the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I) are substantially as Figure 51 shown.

[0192] In a preferred embodiment, in the polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I), the 2-naphthalenesulfonate is

[0193]

[0194] The twenty-second aspect of the present invention provides a crystalline form C of 2-naphthalenesulfonate of a compound represented by formula (I), and its X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 4.50° ± 0.20°, 10.97° ± 0.20°, 13.73° ± 0.20°, 16.66° ± 0.20°, 18.43° ± 0.20°, 19.35° ± 0.20°, and 22.53° ± 0.20°.

[0195] In a certain preferred embodiment, the crystalline form C of 2-naphthalenesulfonate of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 9.67° ± 0.20°, 12.64° ± 0.20°, 14.60° ± 0.20°, 15.19° ± 0.20°, 15.71° ± 0.20°, 17.99° ± 0.20°, 18.16° ± 0.20°, and 18.92° ± 0.20°.

[0196] Preferably, the crystalline form C of 2-naphthalenesulfonate of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 21.25° ± 0.20°, 21.70° ± 0.20°, 21.93° ± 0.20°, 23.41° ± 0.20°, 23.84° ± 0.20°, 24.63° ± 0.20°, 24.83° ± 0.20°, 25.41° ± 0.20°, 25.76° ± 0.20°, 25.97° ± 0.20°, 28.71° ± 0.20°, 29.26° ± 0.20°, and 30.42° ± 0.20°.

[0197] In a preferred embodiment, the crystal form C of the 2-naphthalenesulfonate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle, and may have diffraction peaks at the following 2θ angles: 4.50° ± 0.20°, 9.67° ± 0.20°, 10.97° ± 0.20°, 12.64° ± 0.20°, 13.73° ± 0.20°, 14.60° ± 0.20°, 15.19° ± 0.20°, 15.71° ± 0.20°, 16.66° ± 0.20°, 17.99° ± 0.20°, 18.16° ± 0.20°, 18.43° ± 0.20°, 18.92° ± 0.20°, 19.35° ± 0.20°, 21.25° ± 0.20°, 21.70° ± 0.20°, 21.93° ± 0.20°, 22.53° ± 0.20°, 23.41° ± 0.20°, 23.84° ± 0.20°, 24.63° ± 0.20°, 24.83° ± 0.20°, 25.41° ± 0.20°, 25.76° ± 0.20°, 25.97° ± 0.20°, 28.71° ± 0.20°, 29.26° ± 0.20°, and 30.42° ± 0.20°.

[0198] In a preferred embodiment, the crystal form C of the 2-naphthalenesulfonate of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in terms of 2θ angle that is substantially as Figure 53 shown.

[0199] In a preferred embodiment, the crystal form C of the 2-naphthalenesulfonate of the compound represented by formula (I) has a thermogravimetric analysis chart showing a weight loss of 10.5% when heated from 25°C to 120°C.

[0200] In a preferred embodiment, the crystal form C of the 2-naphthalenesulfonate of the compound represented by formula (I) has a differential scanning calorimetry chart with two endothermic peaks at 49.2 ± 3°C and 73.3 ± 3°C.

[0201] In a preferred embodiment, the differential scanning calorimetry chart and thermogravimetric analysis chart of the crystal form C of the 2-naphthalenesulfonate of the compound represented by formula (I) are substantially as Figure 54 shown.

[0202] In a preferred embodiment, in the crystal form C of the 2-naphthalenesulfonate of the compound represented by formula (I), the 2-naphthalenesulfonate is

[0203]

[0204] The twenty-third aspect of the present invention provides a polymorph A of the malonate salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 5.35° ± 0.20°, 11.38° ± 0.20°, 12.52° ± 0.20°, 17.23° ± 0.20°, 18.80° ± 0.20° and 23.14° ± 0.20°.

[0205] In a certain preferred embodiment, the polymorph A of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 9.20° ± 0.20°, 9.82° ± 0.20°, 10.70° ± 0.20°, 12.91° ± 0.20°, 15.17° ± 0.20°, 16.08° ± 0.20°, 18.33° ± 0.20°, 19.81° ± 0.20°, 20.61° ± 0.20° and 21.09° ± 0.20°.

[0206] Preferably, the polymorph A of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 21.52° ± 0.20°, 21.93° ± 0.20°, 22.49° ± 0.20°, 23.78° ± 0.20°, 24.44° ± 0.20°, 24.92° ± 0.20°, 25.16° ± 0.20°, 25.82° ± 0.20°, 26.42° ± 0.20°, 27.47° ± 0.20°, 28.25° ± 0.20°, 29.72° ± 0.20°, 30.66° ± 0.20° and 32.39° ± 0.20°.

[0207] In a certain preferred embodiment, for polymorph A of the malonate salt of the compound represented by formula (I), the X-ray powder diffraction pattern expressed in terms of 2θ angle may have diffraction peaks at the following 2θ angles: 5.35° ± 0.20°, 9.20° ± 0.20°, 9.82° ± 0.20°, 10.70° ± 0.20°, 11.38° ± 0.20°, 12.52° ± 0.20°, 12.91° ± 0.20°, 15.17° ± 0.20°, 16.08° ± 0.20°, 17.23° ± 0.20°, 18.33° ± 0.20°, 18.80° ± 0.20°, 19.81° ± 0.20°, 20.61° ± 0.20°, 21.09° ± 0.20°, 21.52° ± 0.20°, 21.93° ± 0.20°, 22.49° ± 0.20°, 23.14° ± 0.20°, 23.78° ± 0.20°, 24.44° ± 0.20°, 24.92° ± 0.20°, 25.16° ± 0.20°, 25.82° ± 0.20°, 26.42° ± 0.20°, 27.47° ± 0.20°, 28.25° ± 0.20°, 29.72° ± 0.20°, 30.66° ± 0.20° and 32.39° ± 0.20°.

[0208] In a certain preferred embodiment, for polymorph A of the malonate salt of the compound represented by formula (I), the X-ray powder diffraction pattern expressed in terms of 2θ angle is substantially as Figure 59 shown.

[0209] In a certain preferred embodiment, for polymorph A of the malonate salt of the compound represented by formula (I), its thermogravimetric analysis chart shows a weight loss of 0.3% when heated from 25°C to 100°C.

[0210] In a certain preferred embodiment, for polymorph A of the malonate salt of the compound represented by formula (I), its differential scanning calorimetry chart has an endothermic peak at 112.8 ± 3°C.

[0211] In a certain preferred embodiment, for polymorph A of the malonate salt of the compound represented by formula (I), its differential scanning calorimetry chart and thermogravimetric analysis chart are substantially as Figure 60 shown.

[0212] In a certain preferred embodiment, in polymorph A of the malonate salt of the compound represented by formula (I), the malonate salt is

[0213]

[0214] The twenty-fourth aspect of the present invention provides a polymorph B of the malonate salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in terms of 2θ has diffraction peaks at the following 2θ angles: 7.30° ± 0.20°, 14.74° ± 0.20°, 15.69° ± 0.20°, and 18.24° ± 0.20°.

[0215] In a certain preferred embodiment, the polymorph B of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ further has diffraction peaks at one or more of the following 2θ angles: 9.03° ± 0.20°, 10.58° ± 0.20°, 15.21° ± 0.20°, 16.12° ± 0.20°, 16.35° ± 0.20°, 17.21° ± 0.20°, 17.62° ± 0.20°, 18.65° ± 0.20°, 19.46° ± 0.20°, 20.22° ± 0.20°, 21.33° ± 0.20°, and 21.87° ± 0.20°.

[0216] Preferably, the polymorph B of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ further has diffraction peaks at one or more of the following 2θ angles: 22.22° ± 0.20°, 22.69° ± 0.20°, 22.88° ± 0.20°, 23.84° ± 0.20°, 25.35° ± 0.20°, 25.68° ± 0.20°, 26.13° ± 0.20°, 26.40° ± 0.20°, 27.10° ± 0.20°, 27.57° ± 0.20°, 29.14° ± 0.20°, 30.35° ± 0.20°, 31.07° ± 0.20°, 31.69° ± 0.20°, 32.37° ± 0.20°, and 39.42° ± 0.20°.

[0217] In a preferred embodiment, the polymorph B of the malonate salt of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in 2θ angles, and diffraction peaks can be present at the following 2θ angles: 7.30° ± 0.20°, 9.03° ± 0.20°, 10.58° ± 0.20°, 14.74° ± 0.20°, 15.21° ± 0.20°, 15.69° ± 0.20°, 16.12° ± 0.20°, 16.35° ± 0.20°, 17.21° ± 0.20°, 17.62° ± 0.20°, 18.24° ± 0.20°, 18.65° ± 0.20°, 19.46° ± 0.20°, 20.22° ± 0.20°, 21.33° ± 0.20°, 21.87° ± 0.20°, 22.22° ± 0.20°, 22.69° ± 0.20°, 22.88° ± 0.20°, 23.84° ± 0.20°, 25.35° ± 0.20°, 25.68° ± 0.20°, 26.13° ± 0.20°, 26.40° ± 0.20°, 27.10° ± 0.20°, 27.57° ± 0.20°, 29.14° ± 0.20°, 30.35° ± 0.20°, 31.07° ± 0.20°, 31.69° ± 0.20°, 32.37° ± 0.20°, and 39.42° ± 0.20°.

[0218] In a preferred embodiment, the polymorph B of the malonate salt of the compound represented by formula (I) has an X-ray powder diffraction pattern expressed in 2θ angles that is substantially as Figure 62 shown.

[0219] In a preferred embodiment, the polymorph B of the malonate salt of the compound represented by formula (I) has a thermogravimetric analysis graph showing a weight loss of 0.3% when heated from 25°C to 100°C.

[0220] In a preferred embodiment, the polymorph B of the malonate salt of the compound represented by formula (I) has a differential scanning calorimetry graph with an endothermic peak at 140 ± 3°C.

[0221] In a preferred embodiment, the differential scanning calorimetry graph and thermogravimetric analysis graph of the polymorph B of the malonate salt of the compound represented by formula (I) are substantially as Figure 63 shown.

[0222] In a preferred embodiment, in the polymorph B of the malonate salt of the compound represented by formula (I), the malonate salt is

[0223]

[0224] The twenty-fifth aspect of the present invention provides a polymorphic form C of the malonate salt of the compound represented by formula (I), and its X-ray powder diffraction pattern expressed in terms of 2θ has diffraction peaks at the following 2θ angles: 3.80° ± 0.20°, 15.44° ± 0.20°, 17.77° ± 0.20°, and 19.33° ± 0.20°.

[0225] In a certain preferred embodiment, the polymorphic form C of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ, further has diffraction peaks at one or more of the following 2θ angles: 11.55° ± 0.20°, 14.49° ± 0.20°, 19.73° ± 0.20°, 20.45° ± 0.20°, 21.27° ± 0.20°, and 23.04° ± 0.20°.

[0226] Preferably, the polymorphic form C of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ, further has diffraction peaks at one or more of the following 2θ angles: 23.31° ± 0.20°, 24.40° ± 0.20°, 24.88° ± 0.20°, 25.93° ± 0.20°, 27.64° ± 0.20°, 28.67° ± 0.20°, 29.14° ± 0.20°, 31.26° ± 0.20°, and 32.46° ± 0.20°.

[0227] In a certain preferred embodiment, the polymorphic form C of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ, may have diffraction peaks at the following 2θ angles: 3.80° ± 0.20°, 11.55° ± 0.20°, 14.49° ± 0.20°, 15.44° ± 0.20°, 17.77° ± 0.20°, 19.73° ± 0.20°, 20.45° ± 0.20°, 21.27° ± 0.20°, 23.04° ± 0.20°, 23.31° ± 0.20°, 24.40° ± 0.20°, 24.88° ± 0.20°, 25.93° ± 0.20°, 27.64° ± 0.20°, 28.67° ± 0.20°, 29.14° ± 0.20°, 31.26° ± 0.20°, and 32.46° ± 0.20°.

[0228] In a certain preferred embodiment, the polymorphic form C of the malonate salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in terms of 2θ is substantially as Figure 65 shown.

[0229] In a certain preferred embodiment, for the polymorphic form C of the malonate salt of the compound represented by formula (I), its thermogravimetric analysis chart shows that the weight loss from 25°C to 100°C is 2.7%.

[0230] In a preferred embodiment, the crystalline form C of the malonate of the compound represented by formula (I) has two endothermic peaks at 68.2 ± 3 °C and 108.7 ± 3 °C in its differential scanning calorimetry (DSC) curve.

[0231] In a preferred embodiment, the DSC curve and thermogravimetric analysis (TGA) curve of the crystalline form C of the malonate of the compound represented by formula (I) are substantially as Figure 66 shown.

[0232] In a preferred embodiment, in the crystalline form C of the malonate of the compound represented by formula (I), the malonate is

[0233]

[0234] The twenty-sixth aspect of the present invention provides a pharmaceutical composition comprising:

[0235] any one of the crystalline forms or any one of the salts as described above; and

[0236] pharmaceutically acceptable excipients.

[0237] The twenty-seventh aspect of the present invention provides the use of any one of the crystalline forms, any one of the salts or any one of the pharmaceutical compositions as described above in the preparation of a drug for the treatment and / or prevention of PI3Kα-mediated diseases.

[0238] The twenty-eighth aspect of the present invention provides the use of any one of the crystalline forms, any one of the salts or any one of the pharmaceutical compositions as described above in the preparation of a PI3Kα inhibitor.

[0239] The X-ray powder diffraction peaks of the present invention are expressed in terms of 2θ angle, where "±0.20°" is the allowable measurement error range.

[0240] Without departing from the common general knowledge in the art, the above preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0241] The reagents and raw materials used in the present invention are all commercially available.

[0242] The positive and progressive effects of the present invention are as follows: The crystalline forms of the present invention and the crystalline forms of its salts have one or more advantages such as good solubility, low hygroscopicity and good stability. In particular, the crystalline form A of the maleate of the compound of formula (I) of the present invention has good stability, solubility and low hygroscopicity. BRIEF DESCRIPTION OF THE DRAWINGS

[0243] Figure 1 is an ellipsoid diagram of the three-dimensional structure of the compound of formula (I).

[0244] Figure 2XRPD pattern of crystalline form B of the compound of formula (I).

[0245] Figure 3 DSC and TGA patterns of crystalline form B of the compound of formula (I).

[0246] Figure 4 XRPD pattern of crystalline form C of the compound of formula (I).

[0247] Figure 5 DSC and TGA patterns of crystalline form C of the compound of formula (I).

[0248] Figure 6 XRPD pattern of crystalline form D of the compound of formula (I).

[0249] Figure 7 DSC and TGA patterns of crystalline form D of the compound of formula (I).

[0250] Figure 8 XRPD pattern of crystalline form F of the compound of formula (I).

[0251] Figure 9 DSC and TGA patterns of crystalline form F of the compound of formula (I).

[0252] Figure 10 For the hydrochloride salt crystalline form A of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0253] Figure 11 XRPD pattern of the hydrochloride salt crystalline form A of the compound of formula (I).

[0254] Figure 12 DSC and TGA patterns of the hydrochloride salt crystalline form A of the compound of formula (I).

[0255] Figure 13 For the hydrochloride salt crystalline form B of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0256] Figure 14 XRPD pattern of the hydrochloride salt crystalline form B of the compound of formula (I).

[0257] Figure 15 DSC and TGA patterns of the hydrochloride salt crystalline form B of the compound of formula (I).

[0258] Figure 16 For the p-toluenesulfonate salt crystalline form A of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0259] Figure 17XRPD of p-toluenesulfonate crystal form A of the compound of formula (I).

[0260] Figure 18 DSC and TGA spectra of p-toluenesulfonate crystal form A of the compound of formula (I).

[0261] Figure 19 For 1 HNMR (400 MHz, DMSO-d6) of hydrobromide crystal form A of the compound of formula (I).

[0262] Figure 20 XRPD of hydrobromide crystal form A of the compound of formula (I).

[0263] Figure 21 DSC and TGA spectra of hydrobromide crystal form A of the compound of formula (I).

[0264] Figure 22 For 1 HNMR (400 MHz, DMSO-d6) of hydrobromide crystal form B of the compound of formula (I).

[0265] Figure 23 XRPD of hydrobromide crystal form B of the compound of formula (I).

[0266] Figure 24 DSC and TGA spectra of hydrobromide crystal form B of the compound of formula (I).

[0267] Figure 25 For 1 HNMR (400 MHz, DMSO-d6) of phosphate crystal form A of the compound of formula (I).

[0268] Figure 26 XRPD of phosphate crystal form A of the compound of formula (I).

[0269] Figure 27 DSC and TGA spectra of phosphate crystal form A of the compound of formula (I).

[0270] Figure 28 For 1 HNMR (400 MHz, DMSO-d6) of phosphate crystal form B of the compound of formula (I).

[0271] Figure 29 XRPD of phosphate crystal form B of the compound of formula (I).

[0272] Figure 30 DSC and TGA spectra of phosphate crystal form B of the compound of formula (I).

[0273] Figure 31 For1 HNMR (400 MHz, DMSO-d6).

[0274] Figure 32 XRPD of phosphate crystal form C of the compound of formula (I).

[0275] Figure 33 DSC and TGA diagrams of phosphate crystal form C of the compound of formula (I).

[0276] Figure 34 For oxalate crystal form A of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0277] Figure 35 XRPD of oxalate crystal form A of the compound of formula (I).

[0278] Figure 36 DSC and TGA diagrams of oxalate crystal form A of the compound of formula (I).

[0279] Figure 37 For oxalate crystal form B of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0280] Figure 38 XRPD of oxalate crystal form B of the compound of formula (I).

[0281] Figure 39 DSC and TGA diagrams of oxalate crystal form B of the compound of formula (I).

[0282] Figure 40 For oxalate crystal form C of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0283] Figure 41 XRPD of oxalate crystal form C of the compound of formula (I).

[0284] Figure 42 DSC and TGA diagrams of oxalate crystal form C of the compound of formula (I).

[0285] Figure 43 For oxalate crystal form D of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0286] Figure 44 XRPD of oxalate crystal form D of the compound of formula (I).

[0287] Figure 45 DSC and TGA diagrams of oxalate crystal form D of the compound of formula (I).

[0288] Figure 46 1H NMR (400 MHz, DMSO-d6) of the 2-naphthalenesulfonate salt, polymorph A of the compound of formula (I).

[0289] Figure 47 XRPD of the 2-naphthalenesulfonate salt, polymorph A of the compound of formula (I).

[0290] Figure 48 DSC and TGA curves of the 2-naphthalenesulfonate salt, polymorph A of the compound of formula (I).

[0291] Figure 49 For the 2-naphthalenesulfonate salt, polymorph B of the compound of formula (I) 1 1H NMR (400 MHz, DMSO-d6).

[0292] Figure 50 XRPD of the 2-naphthalenesulfonate salt, polymorph B of the compound of formula (I).

[0293] Figure 51 DSC and TGA curves of the 2-naphthalenesulfonate salt, polymorph B of the compound of formula (I).

[0294] Figure 52 For the 2-naphthalenesulfonate salt, polymorph C of the compound of formula (I) 1 1H NMR (400 MHz, DMSO-d6).

[0295] Figure 53 XRPD of the 2-naphthalenesulfonate salt, polymorph C of the compound of formula (I).

[0296] Figure 54 DSC and TGA curves of the 2-naphthalenesulfonate salt, polymorph C of the compound of formula (I).

[0297] Figure 55 For the maleate salt, polymorph A of the compound of formula (I) 1 1H NMR (400 MHz, DMSO-d6).

[0298] Figure 56 XRPD of the maleate salt, polymorph A of the compound of formula (I).

[0299] Figure 57 DSC and TGA curves of the maleate salt, polymorph A of the compound of formula (I).

[0300] Figure 58 For the malonate salt, polymorph A of the compound of formula (I) 1 1H NMR (400 MHz, DMSO-d6).

[0301] Figure 59XRPD of malonate crystal form A of the compound of formula (I).

[0302] Figure 60 DSC and TGA spectra of malonate crystal form A of the compound of formula (I).

[0303] Figure 61 For malonate crystal form B of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0304] Figure 62 XRPD of malonate crystal form B of the compound of formula (I).

[0305] Figure 63 DSC and TGA spectra of malonate crystal form B of the compound of formula (I).

[0306] Figure 64 For malonate crystal form C of the compound of formula (I) 1 HNMR (400 MHz, DMSO-d6).

[0307] Figure 65 XRPD of malonate crystal form C of the compound of formula (I).

[0308] Figure 66 DSC and TGA spectra of malonate crystal form C of the compound of formula (I). Detailed implementation mode

[0309] The present invention will be further described below by way of examples, but the present invention is not limited to the scope of the examples described herein. The experimental methods without specific conditions in the following examples are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0310] The analysis methods involved in the following examples are described as follows.

[0311] ″Room temperature″ or ″RT″ in the following examples refers to an ambient temperature of about 25 °C.

[0312] X-ray powder diffraction (XRPD)

[0313] The solid samples obtained from the experiment were analyzed using an X-ray powder diffractometer Bruker D8 Advance (Bruker, GER). The 2θ scanning angle ranged from 3° to 45°, the scanning step was 0.02°, and the exposure time was 0.08 seconds. The test method used Cu target Kα1 radiation, with a voltage of 40 kV, a current of 40 mA, and a sample disk with a zero-background sample disk. The current was 40 mA, and the sample disk was a zero-background sample disk.

[0314] Thermogravimetric analysis (TGA)

[0315] The thermogravimetric analyzer model is TADiscovery 550 (TA, US). 2 - 5 mg of the sample was placed in a pre - equilibrated open aluminum sample pan and automatically weighed in the TGA furnace. The sample was heated to the final temperature at a rate of 10 °C / min, with a nitrogen purge rate of 60 mL / min at the sample position and 40 mL / min at the balance position.

[0316] Differential scanning calorimetry (DSC)

[0317] The differential scanning calorimeter model is TADiscovery 250 (TA, US). 1 - 2 mg of the sample was accurately weighed and placed in a punctured DSC Tzero sample pan, and heated to the final temperature at a rate of 10 °C / min, with a nitrogen purge rate of 50 mL / min in the furnace.

[0318] High - performance liquid chromatography (HPLC)

[0319] The high - performance liquid chromatography model is SHIMADZU LC - 20A (Shimadzu, JP), and the test conditions are shown in the following table:

[0320]

[0321] Ion chromatography (IC)

[0322] The ion chromatography model is 925ECO IC (Metrohm, Swiss), and the test conditions are shown in the following table:

[0323]

[0324]

[0325] Example 1: Preparation of the compound of formula (I)

[0326]

[0327] Step 1: Synthesis of Compound 1 - 2

[0328] 1-1 (4.0 g, 9.82 mmol) was added to a pre-dried reaction flask, then tetrahydrofuran (200 mL) was added, and finally Lawesson's reagent (7.94 g, 19.64 mmol) was added. The reaction was carried out at 20 °C with stirring for 12 hours. After the reaction was completed, water was added dropwise to the reaction solution to quench the reaction, and then it was extracted with dichloromethane (100 mL × 3). The organic phases were combined, washed with 100 mL of saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After filtration, it was directly concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 20:1). The purified compound was added to hydrochloric acid aqueous solution (6 M, 100 mL), and then 300 mL of dichloromethane was added for extraction. Sodium carbonate was added to the aqueous phase to adjust the pH until a solid precipitated. The aqueous phase was continuously extracted with 300 mL of dichloromethane, the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain compound 1-2.

[0329] 1 H NMR (400 MHz, CDCl3) δ = 8.08 (d, J = 8.8 Hz, 1H), 8.05 - 7.98 (m, 1H), 7.39 - 7.25 (m, 1H), 7.12 - 7.08 (m, 1H), 6.77 - 6.44 (m, 1H), 6.35 (dd, J = 2.4, 8.7 Hz, 1H), 6.15 (d, J = 2.5 Hz, 1H), 4.85 - 4.72 (m, 1H), 4.65 (dd, J = 4.0, 9.5 Hz, 1H), 4.48 - 4.39 (m, 1H), 4.34 (dd, J = 2.5, 5.0 Hz, 2H), 4.25 - 4.15 (m, 3H), 1.59 (d, J = 6.5 Hz, 3H); MS: m / z = 424.1 [M + 1] + 。

[0330] Step 2: Synthesis of the compound of formula (I)

[0331] 1-2 (20.00 mg, 47.23 μmol) was added to a pre-dried reaction flask, ethanol (5 mL) was added, potassium carbonate (32.64 mg, 236.16 μmol) and O-methylhydroxylamine hydrochloride (19.72 mg, 236.16 μmol) were added. The reaction was carried out with stirring at 80 °C for 12 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, 10 mL of water was added, and then it was extracted with dichloromethane (10 mL × 3). The organic phases were combined. The organic phase was further washed with 10 mL of saturated sodium chloride solution and then dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure; 100 mg was taken, added to n-heptane (2 mL, 20v) to form a suspension, then methyl tert-butyl ether (0.2 mL, 2V) was added, and finally ethanol (0.2 mL, 2V) was added. After stirring at room temperature for 16 hours, it was filtered, and the filter cake was dried under reduced pressure to obtain the compound of formula (I).

[0332] 1 1H NMR (400 MHz, CDCl3) δ = 8.11 - 7.98 (m, 1H), 7.19 (s, 1H), 6.78 - 6.45 (m, 1H), 6.39 (ddd, J = 2.4, 8.8, 13.2 Hz, 1H), 6.24 (dd, J = 2.4, 16.4 Hz, 1H), 4.86 - 4.73 (m, 1H), 4.68 - 4.57 (m, 3H), 4.49 - 4.39 (m, 1H), 4.33 (br d, J = 3.3 Hz, 2H), 4.24 - 4.16 (m, 2H), 3.94 - 3.83 (m, 2H), 3.79 (s, 3H), 1.45 (d, J = 6.5 Hz, 3H); MS: m / z = 437.2 [M + 1] + 。

[0333] Example 2: Single - crystal X - ray diffraction detection and analysis of the compound of formula (I)

[0334]

[0335] Single - crystal cultivation process: Take 10 mg of the compound of formula (I) prepared in Example 1 and add 2 ml of ethanol. Stir until the sample is completely dissolved to obtain a colorless clear solution. Place the sample solution in a 4 - ml semi - sealed sample bottle and slowly volatilize it at room temperature. Colorless needle - shaped crystals are obtained after two weeks. Collect the crystals and collect the diffraction intensity data with a single - crystal X - ray diffractometer (SC - XRD) (D8 - VENTURE). The single - crystal data can determine the absolute configuration of the compound of formula (I), and the molecular formula of this compound is C 19 H 22 F2N6O4. The stereoscopic structure ellipsoid diagram of the compound of formula (I) is shown in Figure 1 . The crystal structure data of the single - crystal of the compound of formula (I) are shown in the following table.

[0336] Crystal data of the single - crystal of the compound of formula (I)

[0337]

[0338]

[0339] Example 3: Preparation of polymorph B of the compound of formula (I)

[0340] Weigh 20.0 mg of the compound of formula (I) prepared in Example 1. Dropwise add 0.4 mL of isopropanol at room temperature to completely dissolve it. After filtration, dropwise add 0.5 mL of n - heptane to the clarified solution until a solid precipitates. Suspend it at room temperature for 1 h, then centrifuge the obtained solid and dry it under vacuum at room temperature for 2 days to obtain polymorph B of the compound of formula (I).

[0341] Figure 2 and 3 shows the XRPD pattern, DSC and TGA patterns of crystalline form B of the compound of formula (I). The XRPD results show that crystalline form B is a solid with medium crystallinity. The DSC pattern shows two endothermic peaks at 58.5 °C and 79.9 °C. TGA shows a weight loss of 3.2% from room temperature to 70 °C and a weight loss of 5.4% from 70 °C to 180 °C.

[0342] The XRPD analysis data are shown in the following table:

[0343]

[0344] Example 4: Preparation of crystalline form C of the compound of formula (I)

[0345] Weigh 19.9 mg of the compound of formula (I) prepared in Example 1, add 0.1 mL of acetonitrile to dissolve it, and add the clear solution dropwise to 1.0 mL of water, and stir at room temperature for 1 day. The resulting solid was centrifuged and dried in vacuo at room temperature for 1 day to obtain crystalline form C of the compound of formula (I).

[0346] Figure 4 and 5 shows the XRPD pattern, DSC and TGA patterns of crystalline form C of the compound of formula (I). The XRPD results show that crystalline form C is a solid with medium crystallinity. The DSC pattern shows two endothermic peaks at 53.0 °C and 95.7 °C. TGA shows a weight loss of 4.7% when heated from room temperature to 100 °C.

[0347] The XRPD analysis data are shown in the following table:

[0348]

[0349] Example 5: Preparation of crystalline form D of the compound of formula (I)

[0350] Weigh 20.1 mg of the compound of formula (I) prepared in Example 1, add 0.1 mL of dimethylformamide to dissolve it, and add the clear solution dropwise to 1.0 mL of water and stir at room temperature for 1 h. The resulting solid was centrifuged and dried in vacuo at room temperature for 2 days, and then XRPD was measured.

[0351] Figure 6 and 7 shows the XRPD pattern, DSC and TGA patterns of crystalline form D of the compound of formula (I). The XRPD results show that crystalline form D is a solid with good crystallinity. The DSC pattern shows two endothermic peaks at 49.7 °C and 106.1 °C. TGA shows a weight loss of 9.6% when heated from room temperature to 75 °C and a weight loss of 2.9% from 75 °C to 120 °C.

[0352] The XRPD analysis data are shown in the following table:

[0353]

[0354]

[0355] Example 6: Preparation of Crystal Form F of the Compound of Formula (I)

[0356] Weigh 19.8 mg of the compound of formula (I) prepared in Example 1, add 2.0 mL of water dropwise at 50 °C to form a suspension, then slowly add 0.8 mL of ethanol dropwise until it becomes clear. After filtering while it is hot, quickly transfer the solution to cool at room temperature. No solid precipitates after standing at room temperature. Place the solution in a refrigerator at 4 °C to cool down. Solids precipitate out. After centrifugal separation, dry it in vacuo at room temperature to obtain crystal form F of the compound of formula (I).

[0357] Figure 8 and 9 The XRPD pattern, DSC and TGA patterns of crystal form F of the compound of formula (I) are shown. The XRPD results show that crystal form F is a solid with good crystallinity. The DSC pattern shows two endothermic peaks at 65.1 °C and 86.6 °C. TGA shows a weight loss of 7.3% from room temperature to 70 °C and a weight loss of 1.7% from 70 °C to 120 °C.

[0358] The XRPD analysis data are shown in the following table:

[0359]

[0360]

[0361] Example 7: Competitive Suspension Experiment of Crystal Forms B, C, D and F of the Compound of Formula (I)

[0362] The competitive suspension experiment was carried out at different temperatures (10 °C, 50 °C or RT) respectively, and the suspension stirring time was 4 days. The results are shown in the following table. In the selected anhydrous solvent system, in the range of 10 °C to 50 °C, crystal form D is thermodynamically more stable than crystal forms B, C and F.

[0363] Results of the Competitive Suspension Experiment

[0364]

[0365] Example 8: Solubility Evaluation of Crystal Form D of the Compound of Formula (I)

[0366] Under the condition of room temperature (~25 °C), weigh a certain amount of crystal form D of the compound of formula (I) and add it to an EP tube. Gradually add a certain amount of water, stir and sonicate to observe whether the solid completely dissolves. Estimate the solubility of the compound in various solvents according to the volume of the solvent used for the solid to completely dissolve. The results show that the solubility of crystal form D is <2 mg / mL.

[0367] Example 9: Hygroscopicity Evaluation of Crystal Form D of the Compound of Formula (I)

[0368] The hygroscopicity was determined using DVS Intrinsic Plus (SMS, UK). The test was carried out in gradient mode with humidity changes of 50% - 95% - 0% - 50% - 0% - 95% - 0%. The humidity change for each gradient within the range of 0% to 90% was 10%. The gradient endpoint was judged by the dm / dt method, with dm / dt less than 0.002% and maintained for 10 minutes as the gradient endpoint, or each gradient was maintained for a maximum of 180 minutes. After the test, XRPD analysis was performed on the sample to confirm whether the solid form had changed. The results are shown in the following table:

[0369]

[0370] Example 10: High Temperature Stability of Crystal Forms B, C, and D of the Compound of Formula (I)

[0371] Using different crystal forms as raw materials, they were heated to the target temperature, kept at a constant temperature for a certain time, cooled to room temperature to obtain solids for XRPD testing. The results are shown in the following table.

[0372] Starting crystal form Target temperature (°C) Constant temperature time (min) Result Crystal form B 65 10 Crystal form B Crystal form D 75 10 Crystal form D Crystal form C 80 10 Crystal form C

[0373] Example 11: Crystal Form A of the Hydrochloride Salt of the Compound of Formula (I)

[0374] Weighed 22.2 mg of the compound of formula (I) prepared in Example 1 and 50 μL of hydrochloric acid (diluted the concentrated acid to a 1 M solution with ethanol, 1 equivalent), added them to 2.0 mL of tetrahydrofuran / cyclohexane (1 / 4, v / v), stirred at room temperature for 3 days, centrifuged the suspension, and dried the solid under vacuum at room temperature to obtain crystal form A of the hydrochloride salt of the compound of formula (I).

[0375] Figure 10 、 11 and 12 show the 1 HNMR (400 MHz, DMSO-d6), XRPD, DSC, and TGA spectra of crystal form A of the hydrochloride salt of the compound of formula (I). 1 The HNMR results showed that most of the peaks were shifted compared to the free form, indicating that the compound of formula (I) had formed a salt. The TGA results showed that there was a 4.0% weight loss during the heating of the sample from RT to 140 °C, and decomposition might occur after 170 °C. The DSC results showed endothermic peaks at around 121.9 and 176.1 °C. The IC results showed that the chloride ion content was 6.10 g / 100 g, and after calculation, the compound of formula (I): chloride ion = 1:1.

[0376] The XRPD analysis data are shown in the following table:

[0377]

[0378]

[0379] Example 12: Crystal Form B of the Hydrochloride Salt of the Compound of Formula (I)

[0380] Weigh 22.0 mg of the compound of formula (I) prepared in Example 1 and 50 μL of hydrochloric acid (dilute the concentrated acid to a 1 M solution with ethanol, 1 equivalent), add them to 1.0 mL of ethanol / n - heptane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and dry the solid under vacuum at room temperature to obtain crystal form B of the hydrochloride salt of the compound of formula (I).

[0381] Figure 13 and 14 Figures 14 and 15 show the 1 1H NMR (400 MHz, DMSO - d6), XRPD, DSC and TGA spectra of crystal form B of the hydrochloride salt of the compound of formula (I). 1 The 1H NMR results show that most of the peaks shift compared with the free form, indicating that the sample forms a salt. The TGA results show that there is a 2.9% weight loss when the sample is heated from RT to 100 °C, and decomposition may occur after 170 °C. The DSC results show endothermic peaks around 78.1, 133.7, 167.5 °C. The IC results show that the compound of formula (I): chloride ion = 1:1.

[0382] The XRPD analysis data are shown in the following table:

[0383]

[0384] Example 13: Crystal Form A of the p - Toluenesulfonate Salt of the Compound of Formula (I)

[0385] Weigh 21.5 mg of the compound of formula (I) prepared in Example 1 and 19.7 mg of p - toluenesulfonic acid monohydrate (2 equivalents), add them to 2.0 mL of acetone / n - heptane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and dry the solid under vacuum at room temperature to obtain crystal form A of the p - toluenesulfonate salt of the compound of formula (I).

[0386] Figure 16 and 17 Figures 17 and 18 show the 1 1H NMR (400 MHz, DMSO - d6), XRPD, DSC and TGA spectra of crystal form A of the p - toluenesulfonate salt of the compound of formula (I). 1The 1H NMR results showed that most of the peaks were shifted compared with the free form, indicating that the sample was salt - formed. The peak at 2.29 ppm indicated the presence of p - toluenesulfonic acid (Compound of formula (I): p - toluenesulfonic acid = 1:2). The TGA results showed that the sample had a weight loss of 1.1% during heating from RT to 70 °C and a weight loss of 2.1% during heating from 70 °C to 150 °C. Decomposition might occur after 200 °C. The DSC results showed endothermic peaks at about 115.0 and 157.3 °C.

[0387] The XRPD analysis data are shown in the following table:

[0388]

[0389]

[0390] Example 14: Crystal form A of p - toluenesulfonate of the compound of formula (I)

[0391] Weigh 22.2 mg of the compound of formula (I) prepared in Example 1 and 28.9 mg of p - toluenesulfonic acid monohydrate (3 equivalents), add them to 2.0 mL of acetone / n - heptane (1 / 4, v / v), stir at room temperature for 1 day, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain crystal form A of p - toluenesulfonate of the compound of formula (I).

[0392] Example 15: Crystal form A of hydrobromide of the compound of formula (I)

[0393] Weigh 21.8 mg of the compound of formula (I) prepared in Example 1 and 50 μL of hydrobromic acid (dilute the concentrated acid to a 1 M solution with ethanol, 1 equivalent), add them to 2.0 mL of tetrahydrofuran / cyclohexane (1 / 4, v / v), stir at room temperature for 3 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain crystal form A of hydrobromide of the compound of formula (I).

[0394] Figure 19 、 20 and 21 show the 1 1H NMR (400 MHz, DMSO - d6), XRPD, DSC and TGA spectra of crystal form A of hydrobromide of the compound of formula (I). 1 The 1H NMR results showed that most of the peaks were shifted compared with the free form, indicating that the sample was salt - formed. The TGA results showed that the sample had a weight loss of 3.0% during heating from RT to 140 °C. Decomposition might occur after 200 °C. The DSC results showed endothermic peaks at about 133.5 and 188.9 °C. The IC results showed that the bromide ion content was 14.41 g / 100 g. After calculation, the compound of formula (I): bromide ion = 1:1.

[0395] The XRPD analysis data are shown in the following table:

[0396]

[0397] Example 16: Crystal Form B of the Hydrobromide Salt of the Compound of Formula (I)

[0398] Weigh 21.8 mg of the compound of formula (I) prepared in Example 1 and 50 μL of hydrobromic acid (the concentrated acid is diluted to a 1 M solution with ethanol, 1 equivalent), add them to 1.0 mL of ethanol / n - heptane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain crystal form B of the hydrobromide salt of the compound of formula (I).

[0399] Figure 22 、 23 and 24 show the 1 1H NMR (400 MHz, DMSO - d6), XRPD, DSC and TGA spectra of crystal form B of the hydrobromide salt of the compound of formula (I). 1 The 1H NMR results show that most of the peaks shift compared with the free form, indicating that the sample forms a salt. The TGA results show that there is a 3.8% weight loss when the sample is heated from RT to 140 °C, and decomposition may occur after 200 °C. The DSC results show endothermic peaks at about 80.3, 159.7, 177.2 °C. The IC results show that the compound of formula (I):bromide ion = 1:1.

[0400] The XRPD analysis data are shown in the following table:

[0401]

[0402]

[0403] Example 17: Crystal Form A of the Phosphate Salt of the Compound of Formula (I)

[0404] Weigh 21.8 mg of the compound of formula (I) prepared in Example 1 and 100 μL of phosphoric acid (the concentrated acid is diluted to a 1 M solution with ethanol, 2 equivalents), add them to 1.0 mL of isopropanol / isopropyl ether (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain crystal form A of the phosphate salt of the compound of formula (I).

[0405] Figure 25 、 26 and 27 show the 1HNMR (400 MHz, DMSO-d6), XRPD, DSC, and TGA spectra. The TGA results showed a 1.1% weight loss of the sample during heating from RT to 100 °C, and decomposition may occur after 170 °C. The DSC results showed endothermic signals at around 36.8 and 177.4 °C. The IC results showed that the content of phosphate ions was 30.23 g / 100 g, and the molar ratio of the compound of formula (I) to phosphate ions was calculated to be 1:2.

[0406] The XRPD analysis data are shown in the following table:

[0407]

[0408] Example 18: Phosphate crystal form B of the compound of formula (I)

[0409] Weigh 21.5 mg of the compound of formula (I) prepared in Example 1 and 100 μL of phosphoric acid (dilute the concentrated acid to a 1 M solution with ethanol, 2 equivalents), add them to 1.0 mL of dichloromethane / cyclohexane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain phosphate crystal form B of the compound of formula (I).

[0410] Figure 28 、 29 and 30 show the 1 HNMR (400 MHz, DMSO-d6), XRPD, DSC, and TGA spectra of phosphate crystal form B of the compound of formula (I). The TGA results showed a 2.6% weight loss of the sample during heating from RT to 60 °C and a 2.2% weight loss during heating from 60 °C to 120 °C, and decomposition may occur after 170 °C. The DSC results showed endothermic peaks at around 48.0, 113.7, and 139.1 °C. The IC results showed that the molar ratio of the compound of formula (I) to phosphate ions was 1:2.

[0411] The XRPD analysis data are shown in the following table:

[0412]

[0413] Example 19: Phosphate crystal form C of the compound of formula (I)

[0414] Weigh 22.0 mg of the compound of formula (I) prepared in Example 1 and 150 μL of phosphoric acid (dilute the concentrated acid to a 1 M solution with ethanol, 3 equivalents), add them to 1.0 mL of isopropanol / isopropyl ether (1 / 4, v / v), stir at room temperature for 1 day, centrifuge the suspension, and vacuum dry the solid at room temperature. After the solid was placed with the lid closed at room temperature for 2 days, part of the solid agglomerated into a gel, and after vacuum drying at 40 °C, phosphate crystal form C of the compound of formula (I) was obtained.

[0415] Figure 31 , 32 and 33 show the 1 HNMR (400 MHz, DMSO-d6), XRPD, DSC, and TGA spectra of crystalline form C of the compound of formula (I). The TGA results show a 1.9% weight loss of the sample during heating from RT to 120 °C, and decomposition may occur after 170 °C. The DSC results show endothermic peaks around 60.3 and 158.0 °C. The IC results show that the compound of formula (I): phosphate ion = 1:2

[0416] The XRPD analysis data are shown in the following table:

[0417]

[0418] Example 20: Oxalate crystalline form A of the compound of formula (I)

[0419] Weigh 21.9 mg of the compound of formula (I) prepared in Example 1 and 9.0 mg of oxalic acid (2 equivalents), add to 1.0 mL of methyl tert-butyl ether, stir at room temperature for 3 days, centrifuge the suspension, and dry the solid under vacuum at room temperature to obtain oxalate crystalline form A of the compound of formula (I).

[0420] Figure 34 , 35 and 36 show the 1 HNMR (400 MHz, DMSO-d6), XRPD, DSC, and TGA spectra of oxalate crystalline form A of the compound of formula (I). 1 The HNMR results show that the peak at 5.49 ppm is shifted compared to the free form, indicating that the sample is salt-formed. The TGA results show a 1.2% weight loss of the sample during heating from RT to 100 °C, and decomposition may occur after 160 °C. The DSC results show endothermic signals around 84.7 and 154.0 °C.

[0421] The XRPD analysis data are shown in the following table:

[0422]

[0423] Example 21: Oxalate crystalline form B of the compound of formula (I)

[0424] Weigh 21.9 mg of the compound of formula (I) prepared in Example 1 and 9.2 mg of oxalic acid (2 equivalents), add to 1.0 mL of ethanol / n-heptane (1 / 4, v / v), stir at room temperature for 3 days, centrifuge the suspension, and dry the solid under vacuum at room temperature to obtain oxalate crystalline form B of the compound of formula (I).

[0425] Figure 37 , 38And 39 show the 1 HNMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of the oxalate polymorph B of the compound of formula (I). 1 The HNMR results show that the peak at 5.49 ppm is shifted compared to the free form, indicating that the sample is salt - formed. The TGA results show that there is a 3.0% weight loss when the sample is heated from RT to 100 °C, and decomposition may occur after 160 °C. The DSC results show endothermic signals at 71.6, 149.5, 156.0 °C.

[0426] The XRPD analysis data are shown in the following table:

[0427]

[0428]

[0429] Example 22: Oxalate polymorph B of the compound of formula (I)

[0430] Weigh 21.7 mg of the compound of formula (I) prepared in Example 1 and 4.8 mg of oxalic acid (1 equivalent), add them to 2.0 mL of tetrahydrofuran / cyclohexane (1 / 4, v / v), stir at room temperature for 3 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain the oxalate polymorph B of the compound of formula (I).

[0431] Example 23: Oxalate polymorph C of the compound of formula (I)

[0432] Weigh 21.7 mg of the compound of formula (I) prepared in Example 1 and 9.2 mg of oxalic acid (2 equivalents), add them to 1.0 mL of isopropanol / isopropyl ether (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain the oxalate polymorph C of the compound of formula (I).

[0433] Figure 40 、 41 And 42 show the 1 HNMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of the oxalate polymorph C of the compound of formula (I). 1 The HNMR results show that the peak at 5.49 ppm is shifted compared to the free form, indicating that the sample is salt - formed. The TGA results show that there is a 3.5% weight loss when the sample is heated from RT to 130 °C, and decomposition may occur after 160 °C. The DSC results show endothermic signals at about 67.8, 150.6 °C.

[0434] The XRPD analysis data are shown in the following table:

[0435]

[0436] Example 24: Oxalate Crystal Form D of the Compound of Formula (I)

[0437] Weigh 21.8 mg of the compound of formula (I) prepared in Example 1 and 9.1 mg of oxalic acid (2 equivalents), add them to 1.0 mL of dichloromethane / cyclohexane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain oxalate crystal form D of the compound of formula (I).

[0438] Figure 43 、 44 and 45 show the 1 1H NMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of oxalate crystal form D of the compound of formula (I). 1 The 1H NMR results show that the peak at 5.49 ppm is shifted compared with the free form, indicating that the sample is salt-formed. The TGA results show that there is a weight loss of 6.8% when the sample is heated from RT to 110 °C, and decomposition may occur after 160 °C. The DSC results show endothermic signals at about 64.9 and 118.6 °C.

[0439] The XRPD analysis data are shown in the following table:

[0440]

[0441] Example 25: 2-Naphthalenesulfonate Crystal Form A of the Compound of Formula (I)

[0442] Weigh 21.9 mg of the compound of formula (I) prepared in Example 1 and 31.1 mg of 2-naphthalenesulfonic acid (3 equivalents), add them to 2.0 mL of acetone / n-heptane (1 / 4, v / v), stir at room temperature for 1 day, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain 2-naphthalenesulfonate crystal form A of the compound of formula (I).

[0443] Figure 46 、 47 and 48 show the 1 1H NMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of 2-naphthalenesulfonate crystal form A of the compound of formula (I). 1The 1H NMR results showed that most of the peaks were shifted compared with the free form, indicating that the sample was salt - formed; the peaks at 8.14, 7.53 ppm, etc. indicated the presence of 2 - naphthalenesulfonic acid (Compound of formula (I): 2 - naphthalenesulfonic acid = 1:3). The TGA results showed that the sample had a weight loss of 3.3% during heating from RT to 100 °C and a weight loss of 4.3% during heating from 100 °C to 170 °C, and decomposition might occur after 200 °C. The DSC results showed endothermic signals at about 51.5, 117.8, 125.1 °C.

[0444] The XRPD analysis data are shown in the following table:

[0445]

[0446]

[0447] Example 26: Crystal form B of the 2 - naphthalenesulfonate of the compound of formula (I)

[0448] Weigh 21.8 mg of the compound of formula (I) prepared in Example 1 and 20.8 mg of 2 - naphthalenesulfonic acid (2 equivalents), add them to 1.0 mL of dichloromethane / cyclohexane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain crystal form B of the 2 - naphthalenesulfonate of the compound of formula (I).

[0449] Figure 49 、 50 Figures 50 and 51 show the 1H NMR (400 MHz, DMSO - d6), XRPD, DSC and TGA spectra of crystal form B of the 2 - naphthalenesulfonate of the compound of formula (I). 1 1H NMR (400 MHz, DMSO - d6), XRPD, DSC and TGA spectra 1 The 1H NMR results showed that most of the peaks were shifted compared with the free form, indicating that the sample was salt - formed; the peaks at 18.14, 7.53 ppm, etc. indicated the presence of 2 - naphthalenesulfonic acid (Compound of formula (I): 2 - naphthalenesulfonic acid = 1:1.5). The TGA results showed that the sample had a weight loss of 4.3% during heating from RT to 130 °C, and decomposition might occur after 200 °C. The DSC results showed an endothermic signal at about 90.5 °C.

[0450] The XRPD analysis data are shown in the following table:

[0451]

[0452]

[0453] Example 27: Crystal form C of the 2 - naphthalenesulfonate of the compound of formula (I)

[0454] Weigh 21.8 mg of the compound of formula (I) prepared in Example 1 and 31.3 mg of 2-naphthalenesulfonic acid (3 equivalents), add them to 1.0 mL of dichloromethane / cyclohexane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum-dry the solid at room temperature to obtain crystalline form C of the 2-naphthalenesulfonate of the compound of formula (I).

[0455] Figure 52 、 53 and 54 show the 1 1H NMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of crystalline form C of the 2-naphthalenesulfonate of the compound of formula (I). 1 The 1H NMR results show that most of the peaks are shifted compared with the free form, indicating that the sample is salt-formed; the peaks at 8.14, 7.53 ppm, etc. indicate the presence of 2-naphthalenesulfonic acid (compound of formula (I): 2-naphthalenesulfonic acid = 1:3). The TGA results show that the sample has a weight loss of 10.5% during heating to 120 °C and may decompose after 200 °C. The DSC results show endothermic signals at about 49.2 and 73.3 °C.

[0456] The XRPD analysis data are shown in the following table:

[0457]

[0458] Example 28: Crystalline form A of the maleate of the compound of formula (I)

[0459] Weigh 327.3 mg (0.75 mmol) of the compound of formula (I) prepared in Example 1, add it to 15 mL of tetrahydrofuran / cyclohexane (1 / 4, v / v) to form a suspension, then add 91.6 mg (1.05 eq.) of maleic acid, suspend at room temperature for 3 days, centrifuge the suspension, and vacuum-dry at 40 °C overnight to obtain crystalline form A of the maleate of the compound of formula (I).

[0460] Figure 55 、 56 and 57 show the 1 1H NMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of crystalline form A of the maleate of the compound of formula (I). 1 The 1H NMR results show that the peak at 5.49 ppm is shifted compared with the free form, indicating that the sample is salt-formed; the peak at 6.24 ppm indicates the presence of maleic acid (compound of formula (I): maleic acid = 1:1). The XRPD results show that crystalline form A of the maleate is a solid with good crystallinity. The TGA results show that crystalline form A of the maleate has a weight loss of 0.3% during heating from RT to 120 °C and may decompose above 170 °C. The DSC results show an endothermic peak at about 176.7 °C.

[0461] The XRPD analysis data are shown in the following table:

[0462]

[0463] Example 29: Form A of the maleate salt of the compound of formula (I)

[0464] Weigh 21.8 mg (0.05 mmol) of the compound of formula (I) prepared in Example 1 and 11.8 mg of maleic acid (2 equivalents), add them to 1.0 mL of methyl tert-butyl ether, stir at room temperature for 3 days, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain Form A of the maleate salt of the compound of formula (I).

[0465] Example 30: Form A of the maleate salt of the compound of formula (I)

[0466] Weigh 21.7 mg (0.05 mmol) of the compound of formula (I) prepared in Example 1 and 5.9 mg of maleic acid (1 equivalent), add them to 2.0 mL of tetrahydrofuran / cyclohexane (1 / 4, v / v), stir at room temperature for 3 days, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain Form A of the maleate salt of the compound of formula (I).

[0467] Example 31: Form A of the maleate salt of the compound of formula (I)

[0468] Weigh 21.7 mg (0.05 mmol) of the compound of formula (I) prepared in Example 1 and 12.0 mg of maleic acid (2 equivalents), add them to 1.0 mL of isopropanol / isopropyl ether (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain Form A of the maleate salt of the compound of formula (I).

[0469] Example 32: Form A of the malonate salt of the compound of formula (I)

[0470] Weigh 21.7 mg of the compound of formula (I) prepared in Example 1 and 10.4 mg of malonic acid (2 equivalents), add them to 1.0 mL of methyl tert-butyl ether, stir at room temperature for 3 days, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain Form A of the malonate salt of the compound of formula (I).

[0471] Figure 58 and 59 60 shows the 1 1H NMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of Form A of the malonate salt of the compound of formula (I). 1The 1H NMR results showed that the peak at 5.49 ppm was shifted compared with the free form, indicating that the sample was salt - formed; the peak at 3.24 ppm indicated the presence of malonic acid (Compound of formula (I): malonic acid = 1:1). The TGA results showed that there was a 0.3% weight loss during heating the sample from RT to 100 °C, and decomposition might occur after 150 °C. The DSC results showed an endothermic peak at about 112.8 °C.

[0472] The XRPD analysis data are shown in the following table:

[0473]

[0474] Example 33: Malonate crystal form B of the compound of formula (I)

[0475] Weigh 22.0 mg of the compound of formula (I) prepared in Example 1 and 10.4 mg of malonic acid (2 equivalents), add them to 1.0 mL of ethanol / n - heptane (1 / 4, v / v), stir at room temperature for 3 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain malonate crystal form B of the compound of formula (I).

[0476] Figure 61 、 62 and 63 show the 1H NMR (400 MHz, DMSO - d6), XRPD, DSC and TGA spectra of malonate crystal form B of the compound of formula (I). 1 HNMR(400MHz,DMSO - d6), XRPD, DSC and TGA spectra. 1 The 1H NMR results showed that the peak at 5.49 ppm was shifted compared with the free form, indicating that the sample was salt - formed; the peak at 2.34 ppm indicated the presence of malonic acid (Compound of formula (I): malonic acid = 1:1). The XRPD results showed that malonate Type B was a solid with good crystallinity. The TGA results showed that there was a 0.3% weight loss during heating the sample from RT to 100 °C, and decomposition might occur after 150 °C. The DSC results showed an endothermic signal at about 140.0 °C.

[0477] The XRPD analysis data are shown in the following table:

[0478]

[0479] Example 34: Malonate crystal form B of the compound of formula (I)

[0480] Weigh 22.0 mg of the compound of formula (I) prepared in Example 1 and 5.3 mg of malonic acid (1 equivalent), add them to 2.0 mL of tetrahydrofuran / cyclohexane (1 / 4, v / v), stir at room temperature for 3 days, centrifuge the suspension, and vacuum - dry the solid at room temperature to obtain malonate crystal form B of the compound of formula (I).

[0481] Example 35: Malonate Crystal Form C of the Compound of Formula (I)

[0482] Weigh 21.5 mg of the compound of formula (I) prepared in Example 1 and 10.5 mg of malonic acid (2 equivalents), add them to 1.0 mL of dichloromethane / cyclohexane (1 / 4, v / v), stir at room temperature for 2 days, centrifuge the suspension, and vacuum dry the solid at room temperature to obtain malonate crystal form C of the compound of formula (I).

[0483] Figure 64 、 65 And 66 shows the 1 1H NMR (400 MHz, DMSO-d6), XRPD, DSC and TGA spectra of malonate crystal form C of the compound of formula (I). 1 The 1H NMR results show that the peak at 5.49 ppm is shifted compared with the free form, indicating that the sample is salt-formed; the peak at 3.24 ppm indicates the presence of malonic acid (Compound of formula (I): Malonic acid = 1:2). The TGA results show that there is a weight loss of 2.7% during the heating of the sample from RT to 100 °C, and decomposition may occur after 150 °C. The DSC results show endothermic signals at about 68.2 and 108.7 °C.

[0484] The XRPD analysis data are shown in the following table:

[0485]

[0486] Example 36: Study on the High Temperature Stability of Different Salts

[0487] Weigh about 5 mg of samples of different crystal forms, heat them to the target temperature at a rate of 30 °C / min, keep them at a constant temperature for 6 minutes, and then cool them to room temperature naturally, and perform XRPD characterization. The experimental results are shown in the following table.

[0488] Starting salt form Temperature (°C) Result p-Toluenesulfonate crystal form A 120 p-Toluenesulfonate crystal form A p-Toluenesulfonate crystal form A 147 Amorphous Maleate crystal form A 150 Maleate crystal form A Oxalate crystal form B 100 Oxalate crystal form B Oxalate crystal form B 150 Oxalate crystal form A Oxalate crystal form A 100 Oxalate crystal form A

[0489] Example 37: Evaluation of the Water Solubility of Different Salts

[0490] Evaluate the solubility of different salt forms in water. At room temperature (~25 °C), weigh about 5 or 10 mg of the sample and add it to an EP tube, add a certain amount of water successively, stir and ultrasonically observe whether the solid is completely dissolved. Estimate the solubility of the compound in various solvents according to the volume of the solvent used for complete dissolution of the solid. The corresponding results are shown in the following table.

[0491]

[0492] Example 38: Evaluation of the Hygroscopicity of Different Salts

[0493] The determination was carried out using DVS Intrinsic Plus (SMS, UK). The test was carried out in a gradient mode with humidity changes of 50% - 95% - 50%, and the humidity change amount for each gradient was 15%. The end of the gradient was judged by the dm / dt method. The gradient end was defined as dm / dt less than 0.002% and maintained for 10 minutes, or the maximum maintenance time for each gradient was 60 minutes. After the test was completed, XRPD analysis was performed on the sample to confirm whether the solid form had changed. The results are shown in the following table.

[0494]

[0495] Example 39: Stability evaluation of maleate polymorph A

[0496] The stability study of maleate polymorph A was carried out under high temperature (60 °C), high humidity (25 °C / 92.5% RH), and accelerated (40 °C / 75% RH) conditions. Samples were taken at 7 days and 15 days respectively for XRPD characterization and purity test. The results are shown in the following table.

[0497] Results of stability study

[0498]

[0499] The XRPD results showed that maleate polymorph A was stable for 15 days under high temperature, high humidity, and accelerated conditions without polymorphic transformation. The HPLC results showed that after being placed for 15 days under high temperature, high humidity, and accelerated conditions, the chemical purity of maleate polymorph A hardly changed significantly.

Claims

1. A salt of a compound represented by formula (I), characterized in that, The salt is maleate, hydrochloride, p-toluenesulfonate, hydrobromide, phosphate, oxalate, 2-naphthalenesulfonate or malonate of the compound represented by formula (I); For example, the salt is any of the following structures:

2. A crystal form of a salt of the compound represented by formula (I); It is characterized in that The crystal form is crystal form A of maleate of the compound represented by formula (I); Crystal form A or B of hydrochloride of the compound represented by formula (I); Crystal form A of p-toluenesulfonate of the compound represented by formula (I); Crystal form A or B of hydrobromide of the compound represented by formula (I); Crystal form A, B or C of phosphate of the compound represented by formula (I); Crystal form A, B, C or D of oxalate of the compound represented by formula (I); Crystal form A, B or C of 2-naphthalenesulfonate of the compound represented by formula (I); or Crystal form A, B or C of malonate of the compound represented by formula (I); Among them, crystal form A of maleate of the compound represented by formula (I) has diffraction peaks at the following 2θ angles in the X-ray powder diffraction pattern expressed in 2θ angle: 7.59°±0.20°, 15.17°±0.20°, 15.96°±0.20°, 16.92°±0.20° and 18.20°±0.20°; Crystal form A of hydrochloride of the compound represented by formula (I) has diffraction peaks at the following 2θ angles in the X-ray powder diffraction pattern expressed in 2θ angle: 5.25°±0.20°, 10.62°±0.20°, 15.98°±0.20° and 21.39°±0.20°; and there is no diffraction peak at 12.04°±0.20°; Crystal form B of hydrochloride of the compound represented by formula (I) has diffraction peaks at the following 2θ angles in the X-ray powder diffraction pattern expressed in 2θ angle: 5.12°±0.20°, 10.37°±0.20°, 12.04°±0.20°, 15.67°±0.20° and 18.20°±0.20°; Crystal form A of p-toluenesulfonate of the compound represented by formula (I) has diffraction peaks at the following 2θ angles in the X-ray powder diffraction pattern expressed in 2θ angle: 4.52°±0.20°, 7.37°±0.20°, 10.99°±0.20°, 12.60°±0.20° and 18.28°±0.20°; Crystal form A of hydrobromide of the compound represented by formula (I) has diffraction peaks at the following 2θ angles in the X-ray powder diffraction pattern expressed in 2θ angle: 5.33°±0.20°, 10.64°±0.20°, 16.00°±0.20° and 21.41°±0.20°; and there is no diffraction peak at at least one of 12.15°±0.20° and 14.00°±0.20°; Crystal form B of hydrobromide of the compound represented by formula (I) has diffraction peaks at the following 2θ angles in the X-ray powder diffraction pattern expressed in 2θ angle: 5.27°±0.20°, 10.50°±0.20°, 12.15°±0.20°, 14.00°±0.20°, 15.75°±0.20°, 21.02°±0.20°; Polymorph A of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 14.33° ± 0.20°, 15.32° ± 0.20°, 17.99° ± 0.20° and 21.37° ± 0.20°; Polymorph B of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 10.23° ± 0.20°, 10.62° ± 0.20°, 13.30° ± 0.20°, 16.94° ± 0.20° and 18.92° ± 0.20°; Polymorph C of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 8.01° ± 0.20°, 8.89° ± 0.20°, 10.58° ± 0.20°, 14.10° ± 0.20°, 15.07° ± 0.20°, 16.31° ± 0.20°, 16.94° ± 0.20°, 17.54° ± 0.20°, 18.55° ± 0.20°, 21.89° ± 0.20° and 22.82° ± 0.20°; Polymorph A of the oxalate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 4.98 ± 0.20°, 5.04 ± 0.20°, 10.72° ± 0.20° and 18.68° ± 0.20°; Polymorph B of the oxalate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 4.96° ± 0.20°, 11.47° ± 0.20°, 12.35° ± 0.20°, 14.97° ± 0.20° and 19.11° ± 0.20°; Polymorph C of the oxalate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 4.81° ± 0.20°, 9.76° ± 0.20°, 11.51° ± 0.20°, 14.99° ± 0.20°, 19.13° ± 0.20°, 19.99° ± 0.20°, 24.30° ± 0.20° and 26.11° ± 0.20°; Polymorph D of the oxalate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 4.57° ± 0.20°, 17.32° ± 0.20°, ​ Polymorph B of the 2-naphthalenesulfonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 5.22° ± 0.20°, 5.76° ± 0.20°, 6.71° ± 0.20°, 11.12° ± 0.20°, 15.67° ± 0.20°, 16.06° ± 0.20°, 16.57° ± 0.20°, 18.18° ± 0.20°, 19.17° ± 0.20° and 21.41° ± 0.20°; Polymorph C of the 2-naphthalenesulfonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 4.50° ± 0.20°, 10.97° ± 0.20°, 13.73° ± 0.20°, 16.66° ± 0.20°, 18.43° ± 0.20°, 19.35° ± 0.20° and 22.53° ± 0.20°; Polymorph A of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 5.35° ± 0.20°, 11.38° ± 0.20°, 12.52° ± 0.20°, 17.23° ± 0.20°, 18.80° ± 0.20° and 23.14° ± 0.20°; Polymorph B of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 7.30° ± 0.20°, 14.74° ± 0.20°, 15.69° ± 0.20° and 18.24° ± 0.20°; Polymorph C of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 3.80° ± 0.20°, 15.44° ± 0.20°, 17.77° ± 0.20° and 19.33° ± 0.20°.

3. The polymorph according to claim 2, wherein, Polymorph A of the maleate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 9.12° ± 0.20°, 10.09° ± 0.20°, 12.60° ± 0.20°, 17.30° ± 0.20°, 17.60° ± 0.20°, 19.79° ± 0.20° and 20.90° ± 0.20°; Polymorph A of the hydrochloride salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 24.75° ± 0.20°, 32.39° ± 0.20° and 37.98° ± 0.20°; Polymorph B of the hydrochloride salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 9.10° ± 0.20°, 9.51° ± 0.20° and 13.86° ± 0.20°; Polymorph A of the p-toluenesulfonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 5.95° ± 0.20°, 7.59° ± 0.20°, 9.06° ± 0.20°, 14.72° ± 0.20°, 15.03° ± 0.20°, 15.28° ± 0.20°, 16.00° ± 0.20°, 16.74° ± 0.20°, 17.85° ± 0.20°, 18.30° ± 0.20°, 18.59° ± 0.20°, 19.11° ± 0.20°, 19.77° ± 0.20°, 20.40° ± 0.20°, 20.78° ± 0.20°, 21.39° ± 0.20° and 22.07° ± 0.20°; Polymorph A of the hydrobromide salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 18.68° ± 0.20°, 24.71° ± 0.20°, 26.38° ± 0.20°, 26.87° ± 0.20° and 32.35° ± 0.20°; Polymorph B of the hydrobromide salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 9.63° ± 0.20°, 16.82° ± 0.20°, 18.33° ± 0.20°, 18.92° ± 0.20°, 19.48° ± 0.20°, 20.61° ± 0.20°, 22.67° ± 0.20° and 22.92° ± 0.20°; Polymorph A of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 9.04° ± 0.20°, 10.95° ± 0.20°, 13.09° ± 0.20°, 16.29° ± 0.20°, 18.82° ± 0.20°, 19.60° ± 0.20°, 20.82° ± 0.20°, 21.78° ± 0.20° and 22.18° ± 0.20°; Polymorph B of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 8.54° ± 0.20°, 16.43° ± 0.20°, 17.30° ± 0.20° and 20.88° ± 0.20°; Polymorph C of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 20.45° ± 0.20° and 25.70° ± 0.20°; Polymorph A of the oxalate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 13.50° ± 0.20°, 17.73° ± 0.20°, and 18.32° ± 0.20°; Polymorph B of the oxalate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 9.45° ± 0.20°, 9.98° ± 0.20°, 15.61° ± 0.20°, 18.47° ± 0.20°, and 20.06° ± 0.20°; Polymorph D of the oxalate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 9.06° ± 0.20°, 11.05° ± 0.20°, 13.57° ± 0.20°, 14.31° ± 0.20°, 16.68° ± 0.20°, 18.88° ± 0.20°, 19.58° ± 0.20°, 20.10° ± 0.20°, and 21.44° ± 0.20°; Polymorph A of the 2-naphthalenesulfonate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 8.97° ± 0.20°, 10.50° ± 0.20°, 10.93° ± 0.20°, 11.80° ± 0.20°, 14.72° ± 0.20°, 15.56° ± 0.20°, 17.99° ± 0.20°, and 18.86° ± 0.20°; Polymorph B of the 2-naphthalenesulfonate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 7.12° ± 0.20°, 9.10° ± 0.20°, 10.42° ± 0.20°, 10.75° ± 0.20°, 15.36° ± 0.20°, 17.79° ± 0.20°, and 18.76° ± 0.20°; Polymorph C of the 2-naphthalenesulfonate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, also has diffraction peaks at one or more of the following 2θ angles: 9.67° ± 0.20°, 12.64° ± 0.20°, 14.60° ± 0.20°, 15.19° ± 0.20°, 15.71° ± 0.20°, 17.99° ± 0.20°, 18.16° ± 0.20°, and 18.92° ± 0.20°; Polymorph A of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 9.20° ± 0.20°, 9.82° ± 0.20°, 10.70° ± 0.20°, 12.91° ± 0.20°, 15.17° ± 0.20°, 16.08° ± 0.20°, 18.33° ± 0.20°, 19.81° ± 0.20°, 20.61° ± 0.20° and 21.09° ± 0.20°; Polymorph B of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 9.03° ± 0.20°, 10.58° ± 0.20°, 15.21° ± 0.20°, 16.12° ± 0.20°, 16.35° ± 0.20°, 17.21° ± 0.20°, 17.62° ± 0.20°, 18.65° ± 0.20°, 19.46° ± 0.20°, 20.22° ± 0.20°, 21.33° ± 0.20° and 21.87° ± 0.20°; Polymorph C of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 11.55° ± 0.20°, 14.49° ± 0.20°, 19.73° ± 0.20°, 20.45° ± 0.20°, 21.27° ± 0.20° and 23.04° ± 0.20°.

4. The polymorph according to claim 2 or 3, characterized in that Polymorph A of the maleate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 21.41° ± 0.20°, 21.70° ± 0.20°, 23.00° ± 0.20°, 23.29° ± 0.20°, 24.85° ± 0.20°, 25.27° ± 0.20°, 26.67° ± 0.20°, 27.39° ± 0.20°, 29.53° ± 0.20°, 30.72° ± 0.20° and 30.79° ± 0.20°; Polymorph B of the hydrochloride salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 16.59° ± 0.20°, 18.88° ± 0.20°, 19.52° ± 0.20°, 20.45° ± 0.20°, 20.96° ± 0.20° and 21.56° ± 0.20°; Polymorph A of the p-toluenesulfonate salt of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 22.75° ± 0.20°, 23.31° ± 0.20°, 23.64° ± 0.20°, 24.48° ± 0.20°, 25.12° ± 0.20°, 25.88° ± 0.20°, 26.07° ± 0.20°, 26.26° ± 0.20°, 26.93° ± 0.20°, 27.33° ± 0.20°, 27.64° ± 0.20°, 28.52° ± 0.20°, 28.91° ± 0.20°, 29.10° ± 0.20°, 29.53° ± 0.20°, 31.42° ± 0.20°, 32.00° ± 0.20°, 32.83° ± 0.20°, 33.77° ± 0.20°, 35.94° ± 0.20°, 36.78° ± 0.20° and 39.50° ± 0.20°; Polymorph B of the hydrobromide salt of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 24.40° ± 0.20°, 25.93° ± 0.20°, 26.38° ± 0.20°, 27.04° ± 0.20°, 27.57° ± 0.20°, 27.96° ± 0.20°, 29.04° ± 0.20°, 29.53° ± 0.20°, 30.40° ± 0.20°, 30.91° ± 0.20°, 31.78° ± 0.20°, 33.53° ± 0.20°, 34.45° ± 0.20° and 37.13° ± 0.20°; Polymorph A of the phosphate salt of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 22.63° ± 0.20°, 22.94° ± 0.20°, 24.11° ± 0.20°, 25.84° ± 0.20°, 26.79° ± 0.20°, 27.10° ± 0.20°, 27.61° ± 0.20°, 28.32° ± 0.20°, 28.64° ± 0.20°, 29.39° ± 0.20°, 30.79° ± 0.20° and 31.43° ± 0.20°; Polymorph B of the phosphate salt of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 21.41° ± 0.20°, 23.52° ± 0.20°, 24.98° ± 0.20°, 25.43° ± 0.20°, 26.13° ± 0.20°, 26.75° ± 0.20°, 27.55° ± 0.20°, 29.24° ± 0.20° and 34.86° ± 0.20°; Polymorph A of the oxalate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 19.09° ± 0.20°, 19.46° ± 0.20°, 20.51° ± 0.20°, 24.42° ± 0.20°, 26.03° ± 0.20°, 26.61° ± 0.20° and 27.04° ± 0.20°; Polymorph B of the oxalate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 20.47° ± 0.20°, 21.37° ± 0.20°, 23.91° ± 0.20°, 24.30° ± 0.20°, 25.04° ± 0.20°, 26.21° ± 0.20°, 27.18° ± 0.20°, 31.67° ± 0.20°, 34.97° ± 0.20° and 40.01° ± 0.20°; Polymorph D of the oxalate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 22.36° ± 0.20°, 24.42° ± 0.20°, 24.63° ± 0.20°, 25.12° ± 0.20°, 26.25° ± 0.20°, 27.53° ± 0.20°, 28.27° ± 0.20°, 29.06° ± 0.20°, 30.52° ± 0.20° and 32.10° ± 0.20°; Polymorph A of the 2-naphthalenesulfonate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 19.31° ± 0.20°, 20.10° ± 0.20°, 20.78° ± 0.20°, 21.93° ± 0.20°, 23.72° ± 0.20°, 25.14° ± 0.20°, 25.84° ± 0.20°, 27.43° ± 0.20° and 28.56° ± 0.20°; Polymorph B of the 2-naphthalenesulfonate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 20.43° ± 0.20°, 21.70° ± 0.20°, 22.36° ± 0.20°, 22.63° ± 0.20°, 23.37° ± 0.20°, 24.32° ± 0.20°, 24.55° ± 0.20°, 25.84° ± 0.20°, 26.91° ± 0.20°, 27.72° ± 0.20°, 28.46° ± 0.20° and 30.17° ± 0.20°; Polymorph C of the 2-naphthalenesulfonate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 21.25° ± 0.20°, 21.70° ± 0.20°, 21.93° ± 0.20°, 23.41° ± 0.20°, 23.84° ± 0.20°, 24.63° ± 0.20°, 24.83° ± 0.20°, 25.41° ± 0.20°, 25.76° ± 0.20°, 25.97° ± 0.20°, 28.71° ± 0.20°, 29.26° ± 0.20° and 30.42° ± 0.20°; Polymorph A of the malonate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 21.52° ± 0.20°, 21.93° ± 0.20°, 22.49° ± 0.20°, 23.78° ± 0.20°, 24.44° ± 0.20°, 24.92° ± 0.20°, 25.16° ± 0.20°, 25.82° ± 0.20°, 26.42° ± 0.20°, 27.47° ± 0.20°, 28.25° ± 0.20°, 29.72° ± 0.20°, 30.66° ± 0.20° and 32.39° ± 0.20°; Polymorph B of the malonate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 22.22° ± 0.20°, 22.69° ± 0.20°, 22.88° ± 0.20°, 23.84° ± 0.20°, 25.35° ± 0.20°, 25.68° ± 0.20°, 26.13° ± 0.20°, 26.40° ± 0.20°, 27.10° ± 0.20°, 27.57° ± 0.20°, 29.14° ± 0.20°, 30.35° ± 0.20°, 31.07° ± 0.20°, 31.69° ± 0.20°, 32.37° ± 0.20° and 39.42° ± 0.20°; Polymorph C of the malonate of the compound of formula (I), X-ray powder diffraction pattern expressed in 2θ angles, further has diffraction peaks at one or more of the following 2θ angles: 23.31° ± 0.20°, 24.40° ± 0.20°, 24.88° ± 0.20°, 25.93° ± 0.20°, 27.64° ± 0.20°, 28.67° ± 0.20°, 29.14° ± 0. ​ Polymorph A of the maleate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 7.59° ± 0.20°, 9.12° ± 0.20°, 10.09° ± 0.20°, 12.60° ± 0.20°, 15.17° ± 0.20°, 15.96° ± 0.20°, 16.92° ± 0.20°, 17.30° ± 0.20°, 17.60° ± 0.20°, 18.20° ± 0.20°, 19.79° ± 0.20°, 20.90° ± 0.20°, 21.41° ± 0.20°, 21.70° ± 0.20°, 23.00° ± 0.20°, 23.29° ± 0.20°, 24.85° ± 0.20°, 25.27° ± 0.20°, 26.67° ± 0.20°, 27.39° ± 0.20°, 29.53° ± 0.20°, 30.72° ± 0.20° and 30.79° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph A of the maleate salt of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 56; Polymorph A of the hydrochloride salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 5.25° ± 0.20°, 10.62° ± 0.20°, 15.98° ± 0.20°, 21.39° ± 0.20°, 24.75 ± 0.20°, 32.39 ± 0.20° and 37.98 ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph A of the hydrochloride salt of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 11; Polymorph B of the hydrochloride salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 5.12° ± 0.20°, 9.10° ± 0.20°, 9.51° ± 0.20°, 10.37° ± 0.20°, 12.04° ± 0.20°, 13.86° ± 0.20°, 15.67° ± 0.20°, 16.59° ± 0.20°, 18.20° ± 0.20°, 18.88° ± 0.20°, 19.52° ± 0.20°, 20.45° ± 0.20°, 20.96° ± 0.20° and 21.56° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph B of the hydrochloride salt of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 14; Crystal form A of the p-toluenesulfonate salt of the compound represented by formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 4.52° ± 0.20°, 5.95° ± 0.20°, 7.37° ± 0.20°, 7.59° ± 0.20°, 9.06° ± 0.20°, 10.99° ± 0.20°, 12.60° ± 0.20°, 14.72° ± 0.20°, 15.03° ± 0.20°, 15.28° ± 0.20°, 16.00° ± 0.20°, 16.74° ± 0.20°, 17.85° ± 0.20°, 18.28° ± 0.20°, 18.30° ± 0.20°, 18.59° ± 0.20°, 19.11° ± 0.20°, 19.77° ± 0.20°, 20.40° ± 0.20°, 20.78° ± 0.20°, 21.39° ± 0.20°, 22.07° ± 0.20°, 22.75° ± 0.20°, 23.31° ± 0.20°, 23.64° ± 0.20°, 24.48° ± 0.20°, 25.12° ± 0.20°, 25.88° ± 0.20°, 26.07° ± 0.20°, 26.26° ± 0.20°, 26.93° ± 0.20°, 27.33° ± 0.20°, 27.64° ± 0.20°, 28.52° ± 0.20°, 28.91° ± 0.20°, 29.10° ± 0.20°, 29.53° ± 0.20°, 31.42° ± 0.20°, 32.00° ± 0.20°, 32.83° ± 0.20°, 33.77° ± 0.20°, 35.94° ± 0.20°, 36.78° ± 0.20° and 39.50° ± 0.20°; Preferably, the X-ray powder diffraction pattern expressed in 2θ angles of crystal form A of the p-toluenesulfonate salt of the compound represented by formula (I) is substantially as shown in Figure 17; Crystal form A of the hydrobromide salt of the compound represented by formula (I), its X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles; 5.33° ± 0.20°, 10.64° ± 0.20°, 16.00° ± 0.20°, 18.68° ± 0.20°, 21.41° ± 0.20°, 24.71° ± 0.20°, 26.38° ± 0.20°, 26.87° ± 0.20° and 32.35° ± 0.20°; Preferably, the X-ray powder diffraction pattern expressed in 2θ angles of crystal form A of the hydrobromide salt of the compound represented by formula (I) is substantially as shown in Figure 20; Polymorph B of the hydrobromide salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 5.27° ± 0.20°, 9.63° ± 0.20°, 10.50° ± 0.20°, 12.15° ± 0.20°, 14.00° ± 0.20°, 15.75° ± 0.20°, 16.82° ± 0.20°, 18.33° ± 0.20°, 18.92° ± 0.20°, 19.48° ± 0.20°, 20.61° ± 0.20°, 21.02° ± 0.20°, 22.67° ± 0.20°, 22.92° ± 0.20°, 24.40° ± 0.20°, 25.93° ± 0.20°, 26.38° ± 0.20°, 27.04° ± 0.20°, 27.57° ± 0.20°, 27.96° ± 0.20°, 29.04° ± 0.20°, 29.53° ± 0.20°, 30.40° ± 0.20°, 30.91° ± 0.20°, 31.78° ± 0.20°, 33.53° ± 0.20°, 34.45° ± 0.20° and 37.13° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph B of the hydrobromide salt of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 23; Polymorph A of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 9.04° ± 0.20°, 10.95° ± 0.20°, 13.09° ± 0.20°, 14.33° ± 0.20°, 15.32° ± 0.20°, 16.29° ± 0.20°, 17.99° ± 0.20°, 18.82° ± 0.20°, 19.60° ± 0.20°, 20.82° ± 0.20°, 21.37° ± 0.20°, 21.78° ± 0.20°, 22.18° ± 0.20°, 22.63° ± 0.20°, 22.94° ± 0.20°, 24.11° ± 0.20°, 25.84° ± 0.20°, 26.79° ± 0.20°, 27.10° ± 0.20°, 27.61° ± 0.20°, 28.32° ± 0.20°, 28.64° ± 0.20°, 29.39° ± 0.20°, 30.79° ± 0.20° and 31.43° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph A of the phosphate salt of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 26; Polymorph B of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 8.54° ± 0.20°, 10.23° ± 0.20°, 10.62° ± 0.20°, 13.30° ± 0.20°, 16.43° ± 0.20°, 16.94° ± 0.20°, 17.30° ± 0.20°, 18.92° ± 0.20°, 20.88° ± 0.20°, 21.41° ± 0.20°, 23.52° ± 0.20°, 24.98° ± 0.20°, 25.43° ± 0.20°, 26.13° ± 0.20°, 26.75° ± 0.20°, 27.55° ± 0.20°, 29.24° ± 0.20° and 34.86° ± 0.20°; preferably, the X-ray powder diffraction pattern of polymorph B of the phosphate salt of the compound of formula (I), expressed in 2θ angles, is substantially as shown in Figure 29; Polymorph C of the phosphate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 8.01° ± 0.20°, 8.89° ± 0.20°, 10.58° ± 0.20°, 14.10° ± 0.20°, 15.07° ± 0.20°, 16.31° ± 0.20°, 16.94° ± 0.20°, 17.54° ± 0.20°, 18.55° ± 0.20°, 20.45° ± 0.20°, 21.89° ± 0.20°, 22.82° ± 0.20° and 25.70° ± 0.20°; preferably, the X-ray powder diffraction pattern of polymorph C of the phosphate salt of the compound of formula (I), expressed in 2θ angles, is substantially as shown in Figure 32; Polymorph A of the oxalate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 4.98 ± 0.20°, 5.04 ± 0.20°, 10.72° ± 0.20°, 13.50° ± 0.20°, 17.73° ± 0.20°, 18.32° ± 0.20°, 18.68° ± 0.20°, 19.09° ± 0.20°, 19.46° ± 0.20°, 20.51° ± 0.20°, 24.42 ± 0.20°, 26.03° ± 0.20°, 26.61° ± 0.20° and 27.04° ± 0.20°; preferably, the X-ray powder diffraction pattern of polymorph A of the oxalate salt of the compound of formula (I), expressed in 2θ angles, is substantially as shown in Figure 35; Polymorph B of the oxalate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 4.96° ± 0.20°, 9.45° ± 0.20°, 9.98° ± 0.20°, 11.47° ± 0.20°, 12.35° ± 0.20°, 14.97° ± 0.20°, 15.61° ± 0.20°, 18.47° ± 0.20°, 19.11° ± 0.20°, 20.06° ± 0.20°, 20.47° ± 0.20°, 21.37° ± 0.20°, 23.91° ± 0.20°, 24.30° ± 0.20°, 25.04° ± 0.20°, 26.21° ± 0.20°, 27.18° ± 0.20°, 31.67° ± 0.20°, 34.97° ± 0.20° and 40.01° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph B of the oxalate of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 38; Polymorph C of the oxalate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles is substantially as shown in Figure 41; Polymorph D of the oxalate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 4.57° ± 0.20°, 9.06° ± 0.20°, 11.05° ± 0.20°, 13.57° ± 0.20°, 14.31° ± 0.20°, 16.68° ± 0.20°, 17.32° ± 0.20°, 18.18° ± 0.20°, 18.88° ± 0.20°, 19.58° ± 0.20°, 20.10° ± 0.20°, 21.44° ± 0.20°, 22.36° ± 0.20°, 22.98° ± 0.20°, 24.42° ± 0.20°, 24.63° ± 0.20°, 25.12° ± 0.20°, 26.25° ± 0.20°, 27.53° ± 0.20°, 28.27° ± 0.20°, 29.06° ± 0.20°, 30.52° ± 0.20° and 32.10° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph D of the oxalate of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 44; Polymorph A of the 2-naphthalenesulfonate of the compound represented by formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 7.06° ± 0.20°, 8.97° ± 0.20°, 10.50° ± 0.20°, 10.93° ± 0.20°, 11.80° ± 0.20°, 14.72° ± 0.20°, 15.56° ± 0.20°, 17.01° ± 0.20°, 17.99° ± 0.20°, 18.37° ± 0.20°, 18.86° ± 0.20°, 19.31° ± 0.20°, 20.10° ± 0.20°, 20.78° ± 0.20°, 21.93° ± 0.20°, 22.42° ± 0.20°, 23.72° ± 0.20°, 24.61° ± 0.20°, 25.14° ± 0.20°, 25.84° ± 0.20°, 27.43° ± 0.20° and 28.56° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph A of the 2-naphthalenesulfonate of the compound represented by formula (I), expressed in 2θ angles, is substantially as shown in Figure 47; Polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 5.22° ± 0.20°, 5.76° ± 0.20°, 6.71° ± 0.20°, 7.12° ± 0.20°, 9.10° ± 0.20°, 10.42° ± 0.20°, 10.75° ± 0.20°, 11.12° ± 0.20°, 15.36° ± 0.20°, 15.67° ± 0.20°, 16.06° ± 0.20°, 16.57° ± 0.20°, 17.79° ± 0.20°, 18.18° ± 0.20°, 18.76° ± 0.20°, 19.17° ± 0.20°, 20.43° ± 0.20°, 21.41° ± 0.20°, 21.70° ± 0.20°, 22.36° ± 0.20°, 22.63° ± 0.20°, 23.37° ± 0.20°, 24.32° ± 0.20°, 24.55° ± 0.20°, 25.84° ± 0.20°, 26.91° ± 0.20°, 27.72° ± 0.20°, 28.46° ± 0.20° and 30.17° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph B of the 2-naphthalenesulfonate of the compound represented by formula (I), expressed in 2θ angles, is substantially as shown in Figure 50; Polymorph C of the 2-naphthalenesulfonate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 4.50° ± 0.20°, 9.67° ± 0.20°, 10.97° ± 0.20°, 12.64° ± 0.20°, 13.73° ± 0.20°, 14.60° ± 0.20°, 15.19° ± 0.20°, 15.71° ± 0.20°, 16.66° ± 0.20°, 17.99° ± 0.20°, 18.16° ± 0.20°, 18.43° ± 0.20°, 18.92° ± 0.20°, 19.35° ± 0.20°, 21.25° ± 0.20°, 21.70° ± 0.20°, 21.93° ± 0.20°, 22.53° ± 0.20°, 23.41° ± 0.20°, 23.84° ± 0.20°, 24.63° ± 0.20°, 24.83° ± 0.20°, 25.41° ± 0.20°, 25.76° ± 0.20°, 25.97° ± 0.20°, 28.71° ± 0.20°, 29.26° ± 0.20° and 30.42° ± 0.20°; Preferably, the X-ray powder diffraction pattern expressed in 2θ angles of polymorph C of the 2-naphthalenesulfonate of the compound of formula (I) is substantially as shown in Figure 53; Polymorph A of the malonate of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles, has diffraction peaks at the following 2θ angles: 5.35° ± 0.20°, 9.20° ± 0.20°, 9.82° ± 0.20°, 10.70° ± 0.20°, 11.38° ± 0.20°, 12.52° ± 0.20°, 12.91° ± 0.20°, 15.17° ± 0.20°, 16.08° ± 0.20°, 17.23° ± 0.20°, 18.33° ± 0.20°, 18.80° ± 0.20°, 19.81° ± 0.20°, 20.61° ± 0.20°, 21.09° ± 0.20°, 21.52° ± 0.20°, 21.93° ± 0.20°, 22.49° ± 0.20°, 23.14° ± 0.20°, 23.78° ± 0.20°, 24.44° ± 0.20°, 24.92° ± 0.20°, 25.16° ± 0.20°, 25.82° ± 0.20°, 26.42° ± 0.20°, 27.47° ± 0.20°, 28.25° ± 0.20°, 29.72° ± 0.20°, 30.66° ± 0.20° and 32.39° ± 0.20°; Preferably, the X-ray powder diffraction pattern expressed in 2θ angles of polymorph A of the malonate of the compound of formula (I) is substantially as shown in Figure 59; Polymorph B of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 7.30° ± 0.20°, 9.03° ± 0.20°, 10.58° ± 0.20°, 14.74° ± 0.20°, 15.21° ± 0.20°, 15.69° ± 0.20°, 16.12° ± 0.20°, 16.35° ± 0.20°, 17.21° ± 0.20°, 17.62° ± 0.20°, 18.24° ± 0.20°, 18.65° ± 0.20°, 19.46° ± 0.20°, 20.22° ± 0.20°, 21.33° ± 0.20°, 21.87° ± 0.20°, 22.22° ± 0.20°, 22.69° ± 0.20°, 22.88° ± 0.20°, 23.84° ± 0.20°, 25.35° ± 0.20°, 25.68° ± 0.20°, 26.13° ± 0.20°, 26.40° ± 0.20°, 27.10° ± 0.20°, 27.57° ± 0.20°, 29.14° ± 0.20°, 30.35° ± 0.20°, 31.07° ± 0.20°, 31.69° ± 0.20°, 32.37° ± 0.20° and 39.42° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph B of the malonate salt of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 62; Polymorph C of the malonate salt of the compound of formula (I), the X-ray powder diffraction pattern expressed in 2θ angles has diffraction peaks at the following 2θ angles: 3.80° ± 0.20°, 11.55° ± 0.20°, 14.49° ± 0.20°, 15.44° ± 0.20°, 17.77° ± 0.20°, 19.73° ± 0.20°, 20.45° ± 0.20°, 21.27° ± 0.20°, 23.04° ± 0.20°, 23.31° ± 0.20°, 24.40° ± 0.20°, 24.88° ± 0.20°, 25.93° ± 0.20°, 27.64° ± 0.20°, 28.67° ± 0.20°, 29.14° ± 0.20°, 31.26° ± 0.20° and 32.46° ± 0.20°; Preferably, the X-ray powder diffraction pattern of polymorph C of the malonate salt of the compound of formula (I) expressed in 2θ angles is substantially as shown in Figure 65.

6. The polymorph according to claim 2, wherein Polymorph A of the maleate salt of the compound of formula (I), its thermogravimetric analysis chart shows a weight loss of 0.3% when heated from 25°C to 120°C; Preferably, its thermogravimetric analysis chart is substantially as shown in Figure 57; Polymorph A of the hydrochloride salt of the compound of formula (I), its thermogravimetric analysis chart shows a weight loss of 4.0% when heated from 25°C to 140°C; Preferably, its thermogravimetric analysis chart is substantially as shown in Figure 12; Polymorph B of the hydrochloride salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 2.9% when heated from 25 °C to 100 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 15; Polymorph A of the p-toluenesulfonate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 1.1% when heated from 25 °C to 70 °C and a weight loss of 2.1% during the process of heating from 70 °C to 150 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 18; Polymorph A of the hydrobromide salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 3.0% when heated from 25 °C to 140 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 21; Polymorph B of the hydrobromide salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 3.8% when heated from 25 °C to 140 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 24; Polymorph A of the phosphate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 1.1% when heated from 25 °C to 100 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 27; Polymorph B of the phosphate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 2.6% when heated from 25 °C to 60 °C and a weight loss of 2.2% during the process of heating from 60 °C to 120 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 30; Polymorph C of the phosphate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 1.9% when heated from 25 °C to 120 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 33; Polymorph A of the oxalate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 1.2% when heated from 25 °C to 100 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 36; Polymorph B of the oxalate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 3.0% when heated from 25 °C to 100 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 39; Polymorph C of the oxalate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 3.5% when heated from 25 °C to 130 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 42; Polymorph D of the oxalate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 6.8% when heated from 25 °C to 110 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 45; Polymorph A of the 2-naphthalenesulfonate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 3.3% when heated from 25 °C to 100 °C and a weight loss of 4.3% when heated from 100 °C to 170 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 48; Polymorph B of the 2-naphthalenesulfonate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 4.3% when heated from 25 °C to 130 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 51; Polymorph C of the 2-naphthalenesulfonate salt of the compound represented by formula (I), whose thermogravimetric analysis chart shows a weight loss of 10.5% when heated from 25 °C to 120 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 54; Polymorph A of the malonate salt of the compound of formula (I), the thermogravimetric analysis chart of which shows a weight loss of 0.3% when heated from 25 °C to 100 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 60; Polymorph B of the malonate salt of the compound of formula (I), the thermogravimetric analysis chart of which shows a weight loss of 0.3% when heated from 25 °C to 100 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 63; Polymorph C of the malonate salt of the compound of formula (I), the thermogravimetric analysis chart of which shows a weight loss of 2.7% when heated from 25 °C to 100 °C; preferably, its thermogravimetric analysis chart is substantially as shown in Figure 66.

7. The polymorph according to claim 2, wherein, Polymorph A of the maleate salt of the compound of formula (I), the differential scanning calorimetry chart of which has an endothermic peak at 176.7 °C ± 3.0 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 57; Polymorph A of the hydrochloride salt of the compound of formula (I), the differential scanning calorimetry chart of which has two endothermic peaks at 121.9 ± 3 °C and 176.1 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 12; Polymorph B of the hydrochloride salt of the compound of formula (I), the differential scanning calorimetry chart of which has three endothermic peaks at 78.1 °C ± 3 °C, 133.7 °C ± 3 °C and 167.5 °C ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 15; Polymorph A of the p-toluenesulfonate salt of the compound of formula (I), the differential scanning calorimetry chart of which has two endothermic peaks at 115.0 ± 3 °C and 157.3 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 18; Polymorph A of the hydrobromide salt of the compound of formula (I), the differential scanning calorimetry chart of which has two endothermic peaks at 133.5 ± 3 °C and 188.9 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 21; Polymorph B of the hydrobromide salt of the compound of formula (I), the differential scanning calorimetry chart of which has three endothermic peaks at 80.3 °C ± 3 °C, 159.7 ± 3 °C and 177.2 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 24; Polymorph A of the phosphate salt of the compound of formula (I), the differential scanning calorimetry chart of which has two endothermic peaks at 36.8 ± 3 °C and 177.4 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 27; Polymorph B of the phosphate salt of the compound of formula (I), the differential scanning calorimetry chart of which has three endothermic peaks at 48.0 °C ± 3 °C, 113.7 ± 3 °C and 139.1 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 30; Polymorph C of the phosphate salt of the compound of formula (I), the differential scanning calorimetry chart of which has two endothermic peaks at 60.3 ± 3 °C and 158.0 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 33; Polymorph A of the oxalate salt of the compound of formula (I), the differential scanning calorimetry chart of which has two endothermic peaks at 84.7 ± 3 °C and 154.0 ± 3 °C; preferably, its differential scanning calorimetry chart is substantially as shown in Figure 36; Polymorph B of the oxalate salt of the compound of formula (I), having three endothermic peaks in its differential scanning calorimetry (DSC) curve at 71.6 °C ± 3 °C, 149.5 ± 3 °C and 156.0 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 39; Polymorph C of the oxalate salt of the compound of formula (I), having two endothermic peaks in its DSC curve at 67.8 ± 3 °C and 150.6 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 42; Polymorph D of the oxalate salt of the compound of formula (I), having two endothermic peaks in its DSC curve at 64.9 ± 3 °C and 118.6 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 45; Polymorph A of the 2-naphthalenesulfonate salt of the compound of formula (I), having three endothermic peaks in its DSC curve at 51.5 ± 3 °C, 117.8 ± 3 °C and 125.1 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 48; Polymorph B of the 2-naphthalenesulfonate salt of the compound of formula (I), having one endothermic peak in its DSC curve at 90.5 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 51; Polymorph C of the 2-naphthalenesulfonate salt of the compound of formula (I), having two endothermic peaks in its DSC curve at 49.2 ± 3 °C and 73.3 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 54; Polymorph A of the malonate salt of the compound of formula (I), having one endothermic peak in its DSC curve at 112.8 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 60; Polymorph B of the malonate salt of the compound of formula (I), having one endothermic peak in its DSC curve at 140 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 63; Polymorph C of the malonate salt of the compound of formula (I), having two endothermic peaks in its DSC curve at 68.2 ± 3 °C and 108.7 ± 3 °C; preferably, its DSC curve is substantially as shown in Figure 66.

8. The polymorph according to claim 2, wherein The maleate salt of the compound represented by formula (I) is The hydrochloride salt of the compound represented by formula (I) is The p-toluenesulfonate of the compound represented by formula (I) is The hydrobromide salt of the compound represented by formula (I) is The phosphate of the compound represented by formula (I) is The 2-naphthalenesulfonate of the compound represented by formula (I) is The malonate of the compound represented by formula (I) is 9. A pharmaceutical composition, characterized in that, it comprises: the salt according to claim 1 or the polymorph according to any one of claims 2-8; and a pharmaceutically acceptable excipient.

10. Use of a salt according to claim 1, a polymorph according to any one of claims 2-8 or a pharmaceutical composition according to claim 9 in the preparation of a medicament for the treatment and / or prevention of PI3Kα-mediated diseases or in the preparation of a PI3Kα inhibitor.

Images